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ABSTRACT

The effect o! !ormulation !actors on the efficacy of
the antiperspirant agent, aluminum chlorhyd.rate, was
studied.

The formulation variables include the various

carrier vehicles for the topically applied active ingredient.
Qunatification of antiperspirant efficiency was evaluated by
a generally accepted gravimetric technique by application o!
a known amount of active ingredient to the axillae o! human
volunteers.
Aluminum chlorhydrate was solubilized in a cream
base, an aqueous lotion, and a hydroalcholic base, and
was suspended in a solid stick.

Aluminum chlorhydroxy

allantoinate was incorporated into all vehicles for its
therapeutic and cosmetic properties.

All test antiperspir-

ant products were selected on the basi_s of cosmetic elegance
and acceptability.
The four vehicles containing aluminum chlorhydrate
were compared for efficacy by a well-recognized gravimetric
procedure during a normal work day in each subject's normal
work environment.

A pretest sweat collection was used as a

blocking factor in designing the 4 by 4, split plot, Latin
Square.

Post-test sweat collection data were evaluated
ii

statistically using the geometric mean of treatment results.
All ratio treatment means were converted to percent sweat
reduction to determine antiperspirant efficiency.
The carrier vehicle does not af'f ect antiperspirant
efficacy.

However, efficacy differences were observed as

a function of solution versus suspension.

Treatment

response in terms of percent sweat reduction was:
lotion,

38.0'~;

aqueous

hydroalcoholic solution, 32.4%; cream base,

31.8%, and solid stick, '-6.:2%. Statistical analysis
indicated that the side treated may be selected randomly
without compromising the results.

Sweat weights may be

af'fected by temperature, muscular exercise, or emotional
stress without affecting antiperspirant effectiveness.

(

iii

ACKNOWLEDGEMENTS
Sincere thanks are extended to Drs. George E. Osborne
and Joan M. Lausier, whose teaching and courses provided the
researcher with an excellent background in cosmetic technology.

Their advice during experimental work, suggestions

during the writing of the thesis, and constructive
criticism throughout the conduct or the project were then,
and are now, greatly appreciated.

The author also is

grateful to Drs. C. T. Rhodes, C. I. Smith, and Anthony
N. Paruta for their criticism, cooperation, .a nd suggestions.

(

The assistance of the other faculty members of the College
of Pharmacy of the University of Rhode Island also is
acknowledged.
Special thanks are offered to Dr. William D. Lawing,
Jr., Department of Computer Science and Experimental
Statistics of the University of Rhode Island, for his
generous assistance in statistical design and analysis;
Dr. R. N. Chadha, Chairman of the Board, Carroll Products,
Inc., Wood River Junction, Rhode Island, and S. B. Mecca,
Chemical Director, Schuylkill Chemical Company, Philadelphia,
for guidance, samples, and continuing interest in this
project; Mr. Greg Adams and Mr. Andrew M. Rubino of Reheis
Chemical Company, Berkeley Heights, New Jersey, for
antiperspirant agents and formulation advice; Mr.
iv

(

Robert

c.

Vonachen of the Kendall Company, Boston, for

Webril pad samples; Cooper Scientific Corporation,
Watertown, Massachusetts, for Surgex samples; and IOI
Americas Incorporated, Wilmington, Delaware, Crod.a,
Incorporated, New York, and Amerchol, FAlison, New Jersey,
for chemical supplies and formularies.
The researcher is extremely grateful to the volunteers
who devoted their time, ideas, and axillae to complete this
study.
The researcher is indebted to her husband, Bruce,
for providing moral support and exceptional editorial and
typing skills.

(

v

TABLE OF CONTENTS
PAGE
ABSTRACT •••••••••••••••••••••••••.••••••••••••••••••••••• ii

ACKN0 1dLEDGEMENTs ••••••••••••••••••••••••••••••••••••••••• iv
TABLE OF CONTENTs •••••••••••••••••••••••••••••••••••••••• vi
LIST OF TABLES••••••••••••••••••••••••••••••••••••••••••vii
FIGURES••••••••••••••••••••••••••••••••••••••••••••••••viii

I.

OBJECTIVES •••••••••••••••••••••••••••••••••••••••••• 1

II.

INTRODUCTION••••••••••••••••••••••••••••••••••••••••3

III.

M.ETHODOLOGY •••••••••••••••••••••••••••••••••••••••• 32

IV.

(

DISCUSSION AND

RESULTS•••••••••••••••••••••••~•••••54

v.

CONCLUSIONS •••••••••••••••••••••••••••••••••••••••• 66

VI.

APPEIIDICES ••••••••••••••••••••••••••••••••••••••••• 67

VII.

REFERENCES ••••••••••••••••••••••••••••••••••••••••• 98

vi

LIST OF TABLES

TABLE

PAGE

1.

Comparison of the Chemical Properties
of Aluminum Chloride and Aluminum
Chlorhydrate ................................ .. • •• 17

2.

Pretest Sweat Collection Data Used for
Blocking 4 by 4, Split Plot, Latin Square •••••••• 46

3.

4 by 4, Split Plot, Latin Square Design •••••••••• 48

4.

Analysis of Variance !or 4 by 4, Split
Plot, Latin Square•••••••••••••••••••••••••••••••51

5.

AllOVA

6.

Antiperspirant Treatment Efficacy
and Dosage•••••••••••••••••••••••••••••••••••••~~

of Post-Test Data •••••••••••••••••••••••••• 5§

vii

(
FIGURES
FIGURE

PAGE

1.

A Diagram of Eccrine and Apocrine Glands in
Relationship to Other Cutaneous Apperid~ea ••••••• 5

2.

A

3.

The Pretest Sweat Ratios of Light-Sweating
Side to Heavy-Sweating Side (L/H) of Subject
Pairs (B) versus Subjects by Sides (t~(BDkp))
Illustrating the Subjects by Sides Interaction
Occurs in Subject Pair 3 •••••••••••••••••••••••• 57

4.

The Effects of Weeks (C) versus Weeks by
Sides ('i._~(CDmp)) Indicating an Interaction
During Week 3, a Possible Result of
Emotional Stress on Sweating •••••••••••••••••••• 59

(

Comp~ison

of pH Values o! Aluminum
Chlorhydrate, Aluminum Sulphate, and
Aluminum Chloride Solutions ••••••••••••••••••••• 18

viii

I.

OBJECTIVES

Many drugs and cosmetics are applied topically,

resulting in various kinds of dermal activity.

These items

include various types and classes of emollients, antiinfectives, sunscreens, keratolytics, antibacterials, and
antiperspirants.

The activity of topically applied drugs

depends on such factors as solubility, particle size,
acid-base function, percutaneous absorption, and stability.
In some instances, drug efficiency has been shown to be
dependent on the carrier vehicle in which the drug is
placed (1-10).
The literature is replete with reports of the
efficacy of dermally applied antiperspirant agents (10-20);
however, there is a paucity of published information on the
effect of vehicle on antiperspirant efficacy.

This gap in

such data became pronounced very recently for two reasons:
the Food and Drug Administration's Over-The-Counter Drug
Review Panel's review of antiperspirants for "• •• safety,
toxicity, and efficacy of the product and its component
ingredients" (21); and the Federal Register May 1977
decision to · phase out fluorocarbon-propelled aerosols (22).
The present study is concerned with:

(

1.

The effect of vehicle on antiperspirant efficacy.

2.

The influence of the active ingredient's state,
1

2
(e.g., suspension versus solution) on antiperspirant
e!!icacy.

3.

Quantification o! antiperspirant efficiency using

a gravimetric technique (23-27) under normal conditions o!
use.
4.

Developing a statistically sound experimental

design, which eliminates side treated differences, to
evaluate antiperspirant efficacy data.

II.
A.

INTRODUCTION

Anatomy and Physiology of the Sweat Glands
The axilla is the cavity beneath the shoulder joint,

commonly referred to as the armpit.
in that it

i~

It is a unique skin site

a moist, intertriginous area containing both

sebaceous glands and sudoriferous or sweat glands.

The

latter are present in the stratum corneum or surface horny
layer, a keratinous layer of flat, denucleated, dead cells,
approximately 600 um thick in the horny pads of the palms
and soles and 15 um thick in the membranous horny layers
such as the axillae (2S').
Perspiration has a physiologically important role.
Insensible perspiration is the loss of water in the form
of vapor from the body into the air through the skin and
respiratory passages.

Sensible perspiration, known as

sweat, is the visible delivery of sweat droplets from the
sweat glands to the skin surface.

The principal functions

of perspiration are the maintenance and control of body
temperature and waste excretion, but it also contributes
to the hydration and plasticization of the stratum
corneum

(29,;o).

There are two distinct functional and anatomical
structures responsible for the production of sensible
perspiration:

the apocrine and eccrine sweat glands.

4
(

The eccrine sweat glands are distributed throughout the
skin surface, with the exception of the lips and genital
organs.

Most are in the palms and soles.

They are tubular

structures consisting of a secretory coil in the lower dermis
with a duct leading directly to the skin surface (Figure 1).
The eccrine sweat glands are well-developed and functional
from birth throughout an individual's life span (32).

They

aid in the regulation of body temperature and maintenance of
skin elasticity (33).
The apocrine glands are distributed among the axillae,
breasts, and urogenital areas.

They are structurally similar,

to the eccrine glands, but they are larger in size and fewer
in number.

The apocrine glands consist of a coiled secretory

tubule in the dermis, leading upward to the duct attached to
a hair follicle.

At least one apocrine gland is attached

to each hair follicle in the axillae (34).

In children,

small, undifferentiated apocrine glands lie deep in the
dermis.

From the seventh year to adolescence the glands

become progressively larger and well-differentiated, but
not functional.

'lbey develop at puberty and remain

functional for life, although they decrease in size and
activity after menopause (35).

Extensive studies of

apocrine gland activity have attempted to correlate
structural and functional variations of the apocrine gland
with hormonal changes without success (36,37).

l

Researchers

regard apocrine sweating as a secondary sexual characteristic, associated with sexual attraction among peoples

5
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\
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~

Figure 1. Diagram of eccrine and apocrine
glands in relationship to other cutaneous
appendages (31).

6
throughout the evolution of the human species
B.

(29,38~0).

The Physiology of Sweat Secretion
Sweat secretion is controlled by the sympathetic

nervous system.

The temperature-regulating center in the

hypothalamus controls thermal sweating, while emotional
sweating, most likely to occur in the palms, soles, and
axillae, is controlled by a cortical center.
Eccrine sweating is a continuous process that is
innervated cholinergically by acetylcholine and
adrenergically by epinephrine.

Ibe nerve fibers

surrounding the eccrine sweat glands respond to emotional
as well as thermal stimuli.
The actions of acetylcholine are either muscarinic
or nicotinic.

Pilocarpine and adrenalin produce a direct

muscarinic response of local eccrine sweating; while
indirect, widespread, nicotinic response will follow
intradermal injections of acetylcholine, metacholine,
and carbachol (41).
Anticholinergics (e.g., atropine) and

gan~lionic

blockers (e.g., hexamethonium) inhibit eccrine sweating.
Atropine has been used clinically to treat hyperhidrosis.
However, the severe parasympathetic side effects and tO:xiicity
associated -with atropine's frequent use and its tendency
to hydrolyse rapidly has limited its usefulness to
experimentation only (42-44).

Various anticholinergic salts

and esters have exhibited greater stability.

In one study

7

(
topical application of 1% scopolamine hydrobrom.ide for five
consecutive days effectively inhibited sweat for one
month (45).

Recent studies showed glycopyrrolates produced

topical suppression of eccrine sweat.

Their use was

accompanied by a marked decrease in local or systemic adverse
effects (46) • .
Apocrine sweating, adrenergically innervated by
epinephrine and emotional stimuli, is an intermittent
process with a refractory period from 24 to 48 hours (33,47).
The physical stimulus of compressing the axillary skin in a
gentle, sliding motion, as in the case of the axilla being
rubbed by a swinging arm during walking, causes the
appearance of apocrine sweat

(~7).

Direct pharmacological stimulation of the apocrine
glands results from intradermal injections of epinephrine,
norepinephrine, and neosynephrine.

Pilocarpine increases

the metabolic rate of apocrine glands.

New evidence suggests

that apocrine sweating may be induced by the contractions
of the muscles surrounding the apocrine sweat tubules and not
solely by adrenergic stimulation (37,44).
Dibenamine selectively inhibits apocrine sweating,
but it is too toxic for clinical use.

The imidazolines,

Regitine and Priscoline, are safe and effective in reducing
apocrine sweating (44).

8
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c.

Perspiration Composition
Perspiration, a mixture of organic and inorganic

matter in a ratio of approximately 1:3, is sterile and
odorless.

Eccrine glands secrete a clear, colorless,

watery fluid that is 99% water.

The remainder is a mixture

of inorganic ions such as sodium, chloride, potassium,
calcium, iron, manganese, magnesium, and copper together
with certain . organic compounds such as lactic, citric, and
ascorbic acids, urea, and nitrogenous compounds (38,48,49).
Eccrine sweat has a pH of 4.0-7.0, the higher pH range
usually from axillary perspiration.

Intertriginous

surfaces, such as the axillae, inhibit sweat evaporation
causing a neutralization and dilution of free acids which
promote hydrolysis of nitrogenous material and result in a
pH increase in sweat on the skin surf ~ce (47).
The apocrine glands secrete an opalescent,
turbid-white fluid that emerges from the hair follicles and
spreads over the skin surface, which, if not diluted by
eccrine sweat, dries rapidly to form a glistening film.
(47,50).

This fluid contains water, sodium chloride,

proteins, lipids, and a high ammonia content which results
in a pH of 6.0-7.5 (49,51).

Generally, the pH of apocrine

sweat is 0.5 pH units higher than eccrine sweat in a given
individual.

~his is attributed to the high ammonia

concentration in apocrine sweat (52).

9
D.

Disorders of the Sweat Glands
There are cases of functional disorders o! the sweat

glands.

Hyperhidrosis or excessive perspiration is one of

the major disorders.

General hyperhidrosis is usually a

result of excessive heat, exertion, or certain drugs as
acetylcholine, or adrenalin.

Local hyperhidrosis usually

affects the axillae or palms or soles.

It originates in the

apocrine glands as a result of stapbylocci infections or from
an initial dermatitis from deodorant/antiperspirant products

(53).

Anhidrosis, a rarely occuring disorder, is the

diminution or even cessation of sweat.

Bromidrosis,

perspiration with an offensive smell, is usually associated
with the apocrine glands and is a direct result of bacterial

(

decomposition.

Chromidrosis, abnormally colored perspiration,

also is attributed to bacterial activity.

Certain toxic and

disease states produce hemahidrosis, which is bloody
perspiration, or urehidrosis, which is perspiration containing urine substances (54).
E.

Perspiration Malodor
Although perspiration secreted by the sweat glands is

sterile and free of odor, the axillae provide an excellent
odor-producing surface.

There are sufficient nutrients from

apocrine secretions plus a warm, moist, neutral pH
medium in which skin bacteria seem to thrive.

Apocrine

secretions that reach the skin surface are subject to
attack by microorganisms, especially gram-positive
staphylocci and diphtheroids, resulting in bacterial

10
(
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decomposition and the characteristic body odor referred to
as caprylic.

Axillary hair and heavy clothing, ideal

collection sites for bacteria, increase perspiration malodor.
Contaminated eccrine secretions, which produce a vague,
indistinct odor unlike apocrine-generated odor, are not
considered the main cause of offensive body odor (36,38,54,
55).
F.

Factors Influencing Perspiration Output

1.

Racial differences.

Perspiration is characteristic

of race, family, and individual.

No significant differences

in sweat volume or sweat distribution have been found in the
eccrine sweating patterns in Negro and Caucausian subjects,
however, apocrine glands of Hegroes are larger, more
numerous, and have shorter refractory periods than Caucausians.
Moreover, chromidrosis occurs more frequently in Negroes.
Mongolian races have relatively inactive apocrine glands.
In any event, females have more, but smaller apocrine glands
than males regardless of race.

Humans produce an average of

one to three pints of eccrine sweat in 24 hours, regardless
of race, sex, ·- or .individual.

Eccrine sweat accounts for the

major portion. o! total volume of axillary perspiration with
only small volumes of apocrine and sebaceous secretions (50).
2.

Therm.al and emotional stimuli.

Quantitative

studies of varying thermal and emotional stimuli have noted
differences in perspiration volume (11,24,56-58).

High

11

temperatures of 80-100°F and high humidities with little air
movement cause an overproduction -of axillary sweat because
cooling is impaired.
YJ.ental stimuli ranging from mental arithmetic to
apprehension to arguments continue to elicit increased
sweating over a long time period of

1-1~

hours (57,58).

Simultaneous emotional and thermal stimuli produce
an additive effect on sweat output.

Minor emotional

stimuli are greatly magnified at higher temperatures,
resulting in an increased axillary sweating rate (58).

3.

Diet and liealth.

Higher metabolic rates,

whether caused by fever, thyroid function, or rich, spicy

(

foods, cause greater heat production and, in turn,
increased sweating (58,59).

A low salt diet of 100

mg/day shows a 20-25% decrease in sweat output compared

to a 40 g/day salt intake diet (58).

Water intake has

little effect on sweat rate, but a substantial loss of
water causes a substantial loss of sodium chloride (29,60).
The response of the sweat glands to a given stimulus,
whether it be thermal, emotional or gustatory, is a
function of the three factors, mainly because it is related
to the acetylcholine produced (61).
4.
rate.

Other factors.

Body posture affects the sweat

If a subject is in a sitting or reclining· position

for an extended time period, the body adjusts and the
sweat rate decreases.

If there is a sudden change in trunk

12

(

position, there is a substantial increase in sweat
rate (11,58).

A dramatic increase in sweat rate and

volume occurs with muscular exercise; this increase is
dependent upon the preexercise sweating rate (62).
There are conflicting reports about the effect of
dominant-handedness on sweating.

In one study, 7ff'fe of the

left-handed subjects and 60% of the right-handed subjects
had a greater sweating rate on the side opposite the
dominant hand (63).

Other studies indicate that the

dominant-handed side sweats more (24).

~here is a significant

variation in right to left axillae sweat ratios from day to
day in the same individual (9,11).

(

Generally, the side with

greater sweat volume remains the same.
Axillary sweat collection devices can greatly alter
the sweating rate.

~b.e force of a vial pressed against

a flat collection pad reduced sweating rate (58).

A

comfortable, yet snugly fitting collection device is
necessary to insure proper sweat collection with no chance
of sweat evaporation.
G.

Control of Perspiration
1.

History.

Throughout history man has searched for

ways to inhibit body odor and perspiration with perfumes and
cosmetics. ·· From ancient Egyptian times to the 1800s bath
oils and perfumes were used to scent the body.

In 1888,

the first trademarked deodorant, Mum, a perfumed wax base
to plug pores, was marketed.

In 1914, the first commercial

13
aluminum chloride-based deodorant, Odo-Ro-No, was
produced.

In addition to its deodorant properties, it

was later discovered to have excellent antiperspirant
activity.

Since then, researchers have tested various

chemicals to help stop odor and wetness.

The introduction

of aluminum chlorhydrate in 1947, an antiperspirant agent
that was non-irritatinf? and minimized fabric damage,
accelerated consumer use of antiperspirant/deodorant
products.

In 1950, hexachlorophene was added to

antiperspirant formulations to enhance their antibacterial properties, but extensive research on the brain
damaging effects of hexachlorophene resulted in termination

(

of its use a decade later.

1'b.e introduction of roll-on

lotions in 1950 and aerosol antiperspirants in 1968
caused the rapid expansion of the antiperspirant market.
A decade later the controversy over the damage to the
ozone layer caused by fluorocarbons in aerosols prompted
their phase out.

1nis action, reported in the

~lay

1977

Federal Register, redirected antiperspirant manufacturers'
attention to the familiar roll-on and stick vehicles.

In

1975, manufacturers began the shift from aerosols to
manual pump sprays.

Today, antiperspirant manufacturers

are evaluating the safety, toxicity, and efficacy of both
their well-established and ' experimental products as
directed by the 1972 Food and Drug Ad.ministration's
Over-The-Counter Drugs Antiperspirant Panel.

This panel

14
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will have a major impact on future trends in the
antiperspirant market (21,22,64-?0).
2.

Mechanism of action of antiperspirants.

Personal

hygiene, deodorants, and antiperspirants are the main
methods of controlling the objectionable aspects o!
perspiration--offensive odor and excessive sweat gland
secretions.
Deodorants help control body odor by masking it and/or
reducing its intensity.

lbey conform to the Food, Drug,

and Cosmetic Act's definition of a cosmetic as "• • • an
article intended to be rubbed, poured, sprinkled, or
sprayed on • • • the human body • • • for cleansing • • •

(

(or) • • • promoting attractiveness •• •" (?1).
Deodorizing agents for the human body include
antibacterials such as neomycin, neutralizing agents such as
sodium bicarbonate, and astringents such as aluminum
chloride (55,72-74).
Antiperspirants control and reduce the flow of
perspiration.

Plechner and deNavarre (75,?6), classify

antiperspirants as drugs because of their anhidrotic
action.

Antiperspirants also conform to the Food, Drug,

and Cosmetic Act's definition of a drug, "• •• articles
intended to affect the structure or any function of the
body of man • • • " (71).
The astringent aluminum salts contained in the
majority of commercial antiperspirants possess both

15
deodorant and antiperspirant actions.

Their deodorant action

involves their antibacterial and chemical properties.

The

acid pH of aluminum compounds, which inhibits bacterial
decomposition of sweat secretions, prevents odor development;
and the chemical combination of the aluminum salts and the
odoriferous substance neutralizes the odor (36,77,78).

The

antiperspirant action of aluminum salts is still disputed.
They may act ··directly on the sweat gland, or form a plug or
block in the sweat duct, or involve the electro-physiological
potential along the sweat duct (?9,80).

Papa (81) studied

the alteration of permeability of eccrine sweat ducts treated
with aluminum chloride.

(

He concluded that the aluminum salt

increases the transductal absorption of sweat.

Hermann's

and Sulzberger's theory (82) is the one that is recognized
most widely.

They observed that antiperspirants produce an

inflammatory reaction accompanied by swelling and an expansion
of the horny layer around the sweat duct causing its
constriction and reducing sweat delivery to the skin
surface (79).
3.

Antiperspirant agents.

A variety of effective

topical antiperspirant agents have been tested.

Anti-

cholinergics such as scopalamine esters are very effective
anhidrotics, but have toxic effects when used on a
long-term basis (41-46).

Formaldehyde and aluminum salts

irritate the skin and damage clothing (14,83).

Zirconium

was very popular in the 1950s, but frequent incidences of

16

granulomas were reported (83-85).
Aluminum chlorhyd.rate is the major

antip~rspirant

agent used in today's commercial products.

It is a basic

aluminum chlorhydroxide complex with an atomic ratio of
aluminum to chloride of 2:1 as compared to
chloride.

1:~

in the aluminum

A 20% w/w solution has a pH of 4.2 compared to

aluminum chloride's pH of 2.0-2.5 (Table 1).

This higher

pH, a result ' of the large proportion of hydroxyl groups,
reduces skin irritation, minimizes clothing destruction,
is consistent with the skin's acid mantle, and prevents
rapid hydrolysis of the antiperspirant agent.

This provides

pH stability over a wide range of concentrations as
(

illustrated in Figure 2 (86).
Aluminum chlorhydrate is very water soluble.

A

50% w/w solution in water is clear, colorless, slightly
viscous; it is soluble with ethyl alcohol, making it ideal
for use in the manual pump sprays.
Aluminum chlorhydrate is available in a variety of
particle sizes making it adaptable for varying uses and
vehicles.

'..lb.e impalpable grade of solid aluminum

chlorhydrate is designed for aerosol and suspensoid stick
application (87).

Sodium aluminum chlorhydroxy lactate,

pH 8.5, was developed for use in sodium stearate based
sticks and systems requiring buffering (88).

Aluminum

chlorhydroxide-proplyene glycol complex is being used more
in aerosols, pump sprays, and stick antiperspirants.
\

It

(

TABLE 1
COMPARISON OF THE CHEMICAL PROPERTIES
OF
ALUMINUM CHLORIDE AND ALUMINUM CHLORHYDRATE

ALUMINUM CHLORHYDRATE

ALUMINUM CHLORIDE
Formula

Al 01

(
pH

Al:Cl

Al 2 (OH)

3

5

Cl

4.00 - 4.25

2.00 - 2.50

2:1

1:3

17

18

pH

5.0

4.0

1.0

5

10

15

20

25

30

35

% Concentration of Salt
Figure 2. Comparison of pH values of aluminum
chlorhydrate, aluminum sulphatet and
aluminum chloride solutions (86;.
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is soluble in both water and anhydrous alcohol up to
concentrations of at least 50% (69,89).
Aluminum chlorhyd.roxy allantoinate, "a stable, white,
odorless powder which combines the antiperspirant and
astringent bacteriostatic properties of aluminum
chlorhyd.rate with the therapeutic and cosmetic properties of
allantoin," (90), is used in conjunction with aluminum
compound antiperspirants.
range of 1-6.1.

It is compatible in a pH

It is employed in concentrations from

0.2-0.3% for its anti-irritant, keratolytic, bacteriostatic,
astringent, moisturizing, anti-pruritic, and healing actions.
It has been proven beneficial in preventing or alleviating

(

dermatitis associated with antiperspirant products (20).
Alcohol-soluble aluminum chlorhydroxy allantoinate is
a molecular form of the allantoin complex used in concentrations from 0.2-0.5% in hydroalcoholic and aerosol
formulations (90).
A modified form of aluminum chlorhydroxy allantoinate
is available for use as the single active ingredient in
concentrations from 6-200fe in antiperspirant lotions and
creams.

A 200fe solution of modified aluminum chlorhydroxy

allantoinate has a pH of 3-5 and contains 19.S°fe aluminum
chlorhydroxide as an active antiperspirant ingredient and
0.2"fe allantoin complex for its therapeutic and cosmetic

effects.

Alcohol-soluble, modified aluminum chlorhydroxy

allantoinate is employed in concentrations from 6-10"fe in
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aerosol antiperspirants (20).
H.

Antiperspirant Formulation and Vehicular Considerations
It is generally recognized that aluminum chlorhydrate

effectively inhibits perspiration, but its activity is
influenced by formulation excipients (e.g., vehicle), mode
of application, concentration of agent, and the amount of
antiperspirant applied (4,6,9,91).

In addition, vehicle

plays an important role in consumer acceptability.

A

vehicle that is physically and chemically compatible with
the antiperspirant agent, is dermatologically safe, and
results in a cosmetically acceptable and elegant product,
is necessary.

(

A number of !actors must be considered when !ormulating antiperspirants.

Aluminum salts other than the alu-

minum chlorhydroxide complexes are sufficiently acidic to
cause a salting out effect of the metal ions; they are
rapidly hydrolyzed, and will react readily with soap bases
such as free stearic acid to form an undesirable product.
To maintain their antiperspirant efficacy and minimize
skin irritation, a pH consistent with the acid mantle of
the skin is sought, and the addition of buffers such as
urea are necessary.

The use of aluminum chlorhydroxide

complexes have solved many of these problems.
Marketed antiperspirant vehicles include creams,
roll-ons, sticks, aerosols, and pump sprays.

0reams and
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roll-ons are oil-in-water or water-in-oil emulsions with the
active ingredient dissolved in the aqueous phase.

The

addition of nonionic surfactants such as Tween 60 and
Arlacel 60 or Arlacel 165 emulsify and thicken the product.
These surfactants are nonirritating to the skin and are
compatible with aluminum salts.

By varying the concentrations

of additive ingredients such as Veegum, cetyl alcohol, or
spermaceti, the viscosity and consistency of the product
can be altered.

Glycerin may be added for emolliency and to

prevent the formation of aluminum crystals (92-94).
To maintain antiperspirant efficacy in a
cosmetically suitable stick, the impalpable grade of

(

aluminum chlorhydrate is suspended in a wax base, or the
aluminum chlorhydroxide-proplyene glycol complex is
dissolved in a stearamide-based stick (95,96).

An

alcoholic diluent and neutral, acidic-aluminum-compatible
gelling agents, such as stearamide and sucrose distearate,
are the building blocks of the stick.
is added for emolliency.

Isopropyl myristate

Volatile silicones are added to

reduce tackiness, drag and drying time (96,97).
Alcohol-soluble forms of aluminum chlorhydroxide
such as aluminum chlorhydrate,

50'~

w/w

solution, or

aluminum cnlorhydroxide-propylene glycol are used in the
commercial manual pump spray antiperspirants.

The

alcohol-based manual pump sprays require the addition of
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valve lubricants, such as stearic acid or Arlamol E, to
prevent aluminum salt crystallization which causes valve
clogging and spray sputtering.

Arlamol E and volatile

silicones are also added for emollience and reduction of
tackiness and drying time.

Powder-in-oil suspensions for

use in pump sprays are being tested (96,98,99).
Perfumes, emollients, thickeners, coloring agents,
and other component ingredients are frequently added to
enhance product appearance and application.

Aerosols re-

quire different formulation considerations.

They are

powder-in-oil suspension concentrates pressurized with a
propellant.

lb.e active ingredient is suspended in the

powder phase, while the oil phase is composed of high
molecular weight carboxylic acid esters and perfume oils.
Epoxy linings prevent the aluminum salt froc corroding
the metal containers.

Aluminum

chlorhydroxide-propy~ene

glycol complex has proven advantageous for use in aerosols
because it is effective, safe, and may be packaged in
low-cost metal containers with fluorocarbon propellants

(70,a9,100,101).
I.

Assessing Antiperspirant Efficacy
1.

In vitro.

In vitro methods are used for

preliminary study of a potential antiperspirant's
activity.

Govett and deNavarre (14) developed the

protein precipitation test, a qualitative or

23
semi-quantitative test for astringency.

One cc of

astringent salt solution is added to a 1:1 mixture of egg
albumin and distilled water.

The rate of protein precipita-

tion, the nature of the precipitate, and solubility
characteristics over a 12-hour period of various
astringents are then evaluated subjectively.

Protein

precipitation testing confirms the superiority of
aluminum chl.o rbydrate over other aluminum salts as a protein
precipitant, despite its higher pH.
A standardized, reproducible frog skin test was
developed by Govett and deNavarre (14) to measure
antiperspirant activity.

(

Frog skin is treated with varying

concentrations of astringent salt solutions.

'lb.e area of

skin shrinkage and decrease in water permeability of the
frog's skin is used to measure the astringent action of
the solutions.

Christian et al. (16,18) expanded this test

by evaluating the effect of antiperspirant preparations on
the permeability of sodium and iodide ions on frog
membranes.

The extent of iodide penetration was measured

by radioactive tracer technique.
2.

In vivo.

Pilocarpine-induced sweating in mouse

and rat foot pads has been used for testing antiperspirant
activity (15).

However, animal eccrine sweat glands differ

histologically from man's (11,102), limiting animal testing
of antiperspirants to measuring irritant potential of the
agent.
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Human testing is necessary for assessing efficacy and
consumer acceptance of a finished antiperspirant product.
The quest !or knowledge of sweat gland function and
antiperspirant efficacy has resulted in a variety o!
techniques for visualizing, assessing, and collecting
sweat (103).
Wada and Taltagaki (104) developed a colorimetric
..

technique that permits visualization of sweat patterns on
the skin.

Skin surfaces painted with a starch-alcoholic

iodine mixture produce a characteristic blue-black color in
distinct patterns corresponding to the presence of active
sweat pores as moisture reaches the skin surface.

(

Papa

(105,106) modified their mixture with a castor oil suspension.
This prevented environmental moisture from interfering with
the results while permitting the presence of sweat droplets
to be visualized.
Visual techniques are used mainly in studying sweat
gland activity (59,10'7.).

To measure antiperspirant

activity a reduction in magnitude of color relative to an
untreated area is evaluated visually.

Sweat patterns and

numerical dot counts taken by blotting paper towels or
pressing ping-pong balls against the tested area have been
adapted to .semi-quantify this method (106,108).

However,

this method does not take into account the size of the
sweat droplets or the sweat intensity (9).

(
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Continuous recording techniques have been used to
quantify sweat production; electronic hygrometers sense and
record perspiration electronically.

While axillary moisture

is continuously removed by a constant flow of gas, an
electronic recording device automatically records and plots
the sweat ratios or perspiration rates.

This procedure

eliminates variables involved in sweat collection, such as
excessive subject movement (the subject is wired and strapped
with electronic devices in a thermal chamber).

Positioning

of the moisture sensing element over the small test area is
critical in obtaining reproducible results.

Tb.is method is

not favored for testing in an area of uneven distribution o!

(

sweat glands such as the axilla.

It has proven useful in

testing on the forearm, an area with an even sweat gland
distribution unaffected by reflexes (11,17,109,110).
In spite of the possible errors inherent in the
gravimetric technique, such as evaporative loss from pads,
lack of distinction between sweat and sebum, positional
variation of pad in the axillary vault, and environmental
and emotional factors affecting human sweating, it is the
most widely used method for testing antiperspirants (4,5,
9,11,12,23-27,38,103).

Since the aim of an antiperspirant

is to cont rol perspiration in humans for everday use in all
types of environments and situations, the gravimetric
technique's antiperspirant efficacy results most closely
resemble consumer use of an antiperspirant product.
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This method is simple, inexpensive, and may be used to test
a large number of subjects simultaneously, whether in
humidity controlled rooms or at ambient temperatures.

It

is best adapted for axillary sweat collections (6,24).
Sweat is collected on tared absorbent pads or silica
gel tins !itted snugly to the axillae.

Arter a given period

or time the pads or tins a:re removed and weighed for
perspiration-

~ach

subject acts as his own control: one

axilla is treated with antiperspirant and the other axilla,
the control, is not treated.
Sweat collections carried out in controlled
temperature rooms of 100°F and

35°~

relative humidity are

preceded by a 40-minute conditioning period in the hot room

(

during which the panelists hold pads to their axillae.

~

hese

pads are discarded, since extremely erratic results in
sweat weight are obtained. during this time.

This is

followed by two or three 20-minute collection periods
using tared pads.

This process may be repeated for 2 to 5

days; ratios are then calculated and averaged (6,11,23-27).
Under ambient conditions, panelists tape or harness
tared pads for a minimum of three hours during a regular
work day (6,9,23-25).
days.

This process is repeated for 2 to 5

In both cases, panelists are requested to remove

axillary hair and to abstain from personal antiperspirant
products for a minimum of one week prior to testing and for
the duration of the test.

Some investigators have allowed
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the use o! deodorant products !or personal comfort (9).
Sweat collection results are evaluated statistically by
the ratio method or by using a geometric mean.

In the ratio

method, both axillae serve as controls for a pretest sweat
collection period.

A pretest perspiration ratio (PR) is

calculated as
• PR (23).
A treatment period is then conducted to obtain a sweat
ratio of treated a.xilla to control a.xilla.

Using an

arithmetic mean, the pretest and posttest ratios are
averaged and antiperspirant efficacy is calculated as
treatment week ratio
)
( 1 - ratio
prior to treatment x 1 00 • percent sweat
reduction (103).
In 1974, Wooding (26) used the geometric mean in a
Sides Subjects Effects Model and produced comparable
antiperspirant efficacy results with the ratio method.

His

model eliminated the need for pretest collection periods,
making it a simple, inexpensive, and convenient method for
obtaining antiperspirant efficacy data.

Other researchers

(4,9,57) have adopted this method to determine antiperspirant
efficacy.

Perspiration weights in milligrams are trans-

formed to natural logarithms before statistical analysis.
The treatment mean (T') and control mean (C') are then
backtransformed to milligrams to calculate the percent
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sweat reduction.
Percent Sweat Reduction• (1 - antilog(T' - C')) x 100 (4)

J.

Previous Studies
The FDA OTC panel directive to review topical drugs

as antiperspirants and their component ingredients !or
their sa!ety, toxicity, and efficacy (4,21) has illuminated
the paucity of information regarding vehicular effects on
antiperspirant efficacy.

Review articles by Uttley (103),

Bakiewicz (11), and Jungermann (6) provide an excellent
source of early antiperspirant efficacy studies.

However,

these studies have been mainly concerned with the efficacy
of the antiperspirant agent itself (10-19).

The majority of

efficacy studies use modifications of Fredell and Read's (23)
gravimetric technique introduced in 1951.

Recent tests

use the same sweat collection procedure, but efficacy
calculations are shifting from their arithmetic mean and
adapting Wooding's (26) geometric mean of calculating
percent sweat reduction.
Majors and Wild (24) observed the influence of
sweating rate, sweat collection conditions, and methods
of data analysis on antiperspirant effectiveness.

Using a

gravimetric technique procedure and a ratio method of
calculation~

they concluded that:

sweat from the dominant

(
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hand axilla is greater; efficacy results are similar
whether taken in a humidity controlled room or during ambient
conditions; axillary sweating ratios are more uniform than
sweating rates from the same panelist (marked variation of
response to antiperspirant application existed among
panelists), and formula additives possibly acting as
irritants to the axilla affect perspiration output and
antiperspira1l.t effectiveness.
Steed (9) collected sweat in silica gel moisture
absorbing tins strapped to the body side of the axilla under
normal conditions of use.

He evaluated three formulations,

one comprised of 25°fe aluminum chlorhydrate in an aqueous
solution thickened with hydroxyethyl cellulose, the second
an 11% aluminum chlorhydrate water-in-oil emulsion aerosol,
and the thirdt .

3.~~

commercial aerosol.

aluminum chlorhydrate suspended in a
Each participant was arbitrarily

designated a treatment a.xilla to which he applied an unknown
amount of test antiperspirant.
using a geometric mean.

Test data were calculated

Percent sweat reduction results

exhibited the superiority of the water-in-oil emulsion aerosol.
He also observed considerable variation in response among
individuals.
Jung~rmann

(6) compared results of antiperspirant

efficacy under normal activity and controlled thermal
environment.

He evaluated a variety of antiperspirant

agents in various vehicles for antiperspirant and
deodorant efficacy, safety, staining potential, and

~o

(

cosmetic acceptability.

Using the ratio method and Student

t-test he found no significant difference among the active
ingredients' effectiveness in the same formulation, but did
notice a difference in activity among vehicles and
concentrations.

He concluded that a controlled thermal

environment places stress on the panelist resulting in poor
experiment reproducibility, while normal conditions provide
reproducible.results and more closely approximate consumer
use and opinions of an antiperspirant.
Wooding et al. (19,26) are innovators of experimental
design and data analysis procedures associated with
gravimetric antiperspirant tests.

Using a Latin Square

design, Wooding et al. (19) applied similar concentrations
of four different antiperspirant agents in aqueous solutions
to the backs of panelists and collected sweat under normal
temperatures in silica gel tins.

The results indicated

that the balanced design and analysis was satisfactory,
statistically sound, and useful in interpreting antiperspirant efficacy data.

A decade later Wooding and

Finklestein (26) developed a Sides Subjects Effects
Model (SSll-1) using a cross-over design.

They compared

efficacy results under thermal and ambient temperatures
using the arithmetic mean of the ratio method and the
geometric mean of their method.

The SSEM not only

gave comparable results to the well-established ratio
method, but also eliminated the need for pretest ratios.
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O'Malley and Christian (17) used a continuous
recording method to evaluate perspiration properties of
six commercial antiperspirant agents and three commercial
bases in the forms of a stick, a cream, and a lotion in comparison with a 24% w/w aluminum sulfate solution.

All

preparations were applied to the subjects' forearms, and
the subjects were exposed to varying thermal conditions.
A ratio method of calculation indicated that aluminum
methionate was the most effective agent and that vehicle
did not affect antiperspirant efficacy.
Bretschneider et al. (4) used a gravimetric
axillary procedure in a humidity-controlled room to
evaluate efficacy of aluminum chlorhydrate type
ingredients.

Antiperspirant efficacy was calculated using

the geometric mean.

They tested varying aluminum to

halide ratios, multi-ingredient formulations, varying
concentrations of single-ingredient formulations, and
aqueous versus hydroalcoholic dose forms for efficacy.
Definitive results were obtained that showed an increased
effectiveness of aqueous vehicles and that optimum
concentration efficacy reached a maximum of 15°fe aluminum
chlorhydrate rather than a plateau.

III.

A.

METHODOLOGY

Materials
The following chemicals were used in this study and

have been classified by lot number and manufacturer.
Glycine, (lot# G620-1) 1
Arlacel 60, sorbit~ monostearate, (lot# 0602067) 2
Cetyl Alcohol, N. F., (lot# ?5039000?) 2
Spermaceti, U. S. P., granular, (lot# 0608196) 2
Titanium Dioxide,

u. s.

P., powder, (lot# C612248) 2

Amerchol CAB, (lot# 153)3
Amerchol L-101, multisterol extract, (lot# 932)3
Modulan, acetylated lanolin, (lot# 351)3
Solulan 16, ethoxylated (16) lanolin alcohol, (lot# 1278)3
Solulan 98, acetyl p. o. e. (10) lanolin alcohol
complex, (lot# 363)3
Glycerine, 96%, Crystal White, (lot# 78-206) 4

1.

Aldrich Chemical Co., Inc., Milwaukee, Wisconsin.

2.

Amend Drug and Chemical Co., Irvington, New Jersey.

3.

Amerchol, Edison, New Jersey.

4.

Colgate-Palmolive Co., New York, New York.
32
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Crodamol IPH, isopropyl myristate, (lot# 331)5
Crodesta A 10, acetylated sucrose distearate, (lot# 3600403-2)5
Procetyl AWS, alcohol and water soluble cetyl alcohol,
(lot# 66)5
Super Hartolan, lanolin alcohol, (lot# 428?0)5
Gulf ax, paraffin, (lot# C211K-I-LP) 6
Arlacel 165, glycerol monostearate and polyoxyethylene
stearate, . (lot# 1855) 7
Arlacel 186, glycerol fatty acid ester, (lot# 391)7
Arlamol E, polyoxypropylene 15 stearyl ether, (lot# 4453B)7
Myrj 52, polyoxyl 40 stearate, U.

s.

P., (lot# 280)7

Tween 60 SD, sorbitan monostearate, (lot # 1153)7
G-2162, polyoxyethylene (25) propylene glycol stearate,
(lot# 119)7

(

p-Dioxane, (lot# 64) 8
Veegum, colloidal magnesium aluminum silicate, (lot# 0612248)9
Chlorhydrol, 5C1fo w/w Solution, aluminum chlorhydroxide
complex, (lot# 6115) 10

5.

Croda, Inc., New York, New York.

6.

Gulf Oil Corp., Houston, Texas.

?. ICI Americas Inc., Wilmington, Delaware.
8.

Matheson, Coleman, and Bell, E. Rutherford, New Jersey.

9. R. T. Vanderbilt Co., Inc., New York, New York.
10. Reheis Chemical Co., Berkeley Heights, New Jersey.

MicroDry, Ultrafine, impalpable grade of solid aluminum
chlorbydroxide complex, (lot# 5783) 10
Rebydrol, aluminum chlorhyd.roxide-propylene glycol complex,
(lot # 822) 10
Candelilla Wax, (lot# TL83074) 11
Carnauba Wax Yellow #1, ~lot# 65204) 11
Fluid Silicones 200, 1000· cps, (lot# AA6045) 11
Propylene Glycol, U. S. P., (lot# S-353998) 11
Ozokerite Wax, white, (lot# N?0970) 11
Sodium Lau.ryl Sulfate, dental grade, (lot# 0713284) 11
Tenox BHT, (lot# 101267) 11
Stearic Acid, U.

s.

P., (lot# F-1-0562) 11

Alcohol soluble aluminum chlorhydroxy allantoinate
modified12
Alcohol soluble aluminum chlorhydroxy allantoinate
molecular12
Aluminum chlorhydroxy allantoinate 12
Aluminum chlorhydroxy allantoinate modified12

10.

Reheis Chemical Co., Berkeley Heights, New Jersey.

11.

Ruger Chemical Co., Irvington, New Jersey.

12.

Schuylkill Chemical Co., Philadelphia, Pennsylvania.
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Glassware and common laboratory equipment were supplied
by the College o! Pharmacy of the University o! Rhode Island.
Additional supplies and their manufacturers are:
Cotton tipped applicators, 6", (lot# 22-9186),
ABCO Distributors Inc., Milwaukee, Wisconsin.
Dermicel Hypoallergenic Cloth Tape, 2" by 10 yds., Johnson
and Johnson, New Brunswick, New Jersey.
Ivory Soap, Proctor and Gamble, Cincinnati, Ohio.
Surgex Hair Remover Cream, Cooper Scientific Corporation,
Watertown, Massachusetts.
Webril Handi Pads, Kendall Fiber Products Division,
Walpole, Massachusetts.

(

Ziploc Storage Bags, 17.8 cm by 20.3 cm by 1.75 mil,
The Dow Chemical Company, Indianapolis, Indiana.
B.

Methodology
1.

Antiperspirant formulations.

To limit the

variables in this study, an effective active ingredient
was selected to be incorporated in four different vehicles
after two antiperspirant agents were tested for solubility
and physical and chemical compatibility.
The active agents, modified aluminum chlorhydroxy
allantoinate and aluminum chlorhydrate, were tested for
solubility ·and compatibility in four widely used vehicular
forms, a cream base, an aqueous roll-on lotion, a
solid stick, and an alcohol base such as one used
in the manual pump sprays (Appendix A).

All products
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were formulated by the researcher to ensure experimental
control over concentrations o! active ingredients and
materials used for component ingredients.
Preliminary dose form and solubility studies were
performed with these agents in varying concentrations of
byd.roalcoholic, propylene glycol/water, propylene
glycol/alcohol, and dioxane/water solutions.

Noting the

concentrations of agent necessary for antiperspirant
activity in compatible dose forms led to the selection of
20'4 aluminum chlorbyd.rate as the antiperspirant agent and

0.25% aluminum chlorhydroxy allantoinate for its therapeutic
and cosmetic properties.
Three different grades of aluminum chlorhydroxide

(

complex--Chlorhydrol, 5CY14 w/w solution, MicroDry,
Ultra.fine, and Rehydrol--were tested in suitable dose
forms.

Chlorhydrol, 50% w/w solution was employed in

concentrations of 40'4 (92-94) in preliminary formulations
of creams, lotions, and alcohol based solutions (Appendix A).
Twenty percent MicroDry, Ultra.fine was incorporated directly
into a variety of solid sticks.
equivalent to
complex,

Since Rehydrol (89,111) is

75% by weight of the aluminum chlorhydroxide

26.?~

Rehyd.rol was used in formulating sticks and

alcohol-based solutions to maintain an equivalent amount of
active ingredient with the preparations containing
Chlorhyd.rol, 501G w/w solution.

For its beneficial

therapeutic and cosmetic properties,

0.25% aluminum
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chlorhydroxy allantoinate (20,90) was incorporated into
preliminary formulations of creams and lotions, and the
alcohol-soluble form was used in the stick and alcohol
solutions.
Modification of established formulations (92-98)
was necessary to prepare a simple, yet cosmetically
acceptable vehicle.

All preliminary formulations were

tested and compared for physical and chemical compatibility,
stability, and consumer acceptability.

One product from

each vehicular form was selected for use as the test
antiperspirant.
formulated.

Several cream antiperspirants were

Most were similar in composition to the

test cream antiperspirant.

Forty percent Chlorhydrol,

50% w/w solution, and 0.25% aluminum chlorhydroxide
allantoinate were incorporated in a cream base.

The

test cream (93) antiperspirant contained

%,

weight

A.

Cetyl alcohol •••••••••••••••••••••••••••••••••• 5.00
Arlacel 165••••••••••••••••••••••••••••••••••••5.00

B.

Distilled water•••••••••••••••••••••••••••••••49.?5
Aluminum chlorhydro:xy allantoinate ••••••••••••• 0.25
Chlorhydrol, 50'fe w/w solution ••••••••••••••••• 40.00
100.00

Phase A contained cetyl alcohol for stiffening,
consistency, and texture.

Arlacel 165
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served both as emulsifier (HLB • 11) and a thickener (112).
This phase was heated slowly with constant stirring to
?0°0.

The water phase, B, consisting o! suitable

concentrations of the active ingredient and the allantoin
complex, was heated to 72-C to allow for rapid cooling.
B was added to A at the same temperature with constant
stirring to permit proper emulsification.

The emulsion

was stirred rapidly until it set at about 40°0 and then
packaged in opaque ointment jars.
This cream was white, fluffy, easy to apply, and
quick-drying.

An application o! 500

mg

of the antiperspirant

cream to each axilla provided 100 mg of active ingredient

(

in solution.
The test lotion antiperspirant contained

%, weight
A.

Veegum•••••••••••••••••••••••••••••••••1.00
Water, distilled•••••••••••••••••··~··50.75

B.

Arlacel 165 •••••••••••••••••••••••••••• a.oo

c.

Chlorhyd.rol, 5o:'fe w/w solution ••••••••• 40.00
Aluminum chlorhydroxy allantoinate ••••• 0.25
100.00

Veegum was added slowly with continual agitation to water
at room temperature until a smooth mixture resulted.
mixture wa$ then heated to 70°0.

The

Veegum is frequently

used in roll-on lotions to increase the viscosity.
also is used as an emulsion stabilizer.

It

Arlacel 165 was

heated separately to 75°0, then added to A with agitation
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and mixed while cooling to 50°0.

The allantoin complex was

dissolved in Chlorhydrol, SO'fe w/w solution at 50°0 to form
a clear solution.

This solution was added to the above

mixture and mixed constantly until it cooled to 38°0.
This aqueous lotion provided 100 mg of active
ingredient in solution per 500 mg of lotion.
lotion both contained Arlacel 165.

The cream and

In the cream, the Arlacel

165 was used' to emulsii'y the oil and water phases, while in
the lotion, it was used as a thickener and stabilizer.

A

trial test showed that the lotion could be applied
successfully from a roll-on applicator.

This white, viscous,

quick-drying antiperspirant was considered the most elegant

(

and cosmetically acceptable vehicle by the volunteers.
Stick formulations introduced a variety of formulation
problems.

The acidic aluminum salts are not suitable for

use in a sodium stearate-based stick.

Stearamide, used

frequently as an antiperspirant stick building block with
great success in industry, was unobtainable.

Therefore, a

sus~

pensoid stick containing MicroDry, Ultrafine was formulated.
A solid stick antiperspirant (97) that was quick-drying
and of suitable consistency for axillary application contained
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A.

Crodesta A 10••••••••••••••••••••••••••••••••••••••••38.5
Procetyl AWS••••••••••••••••••••••••••••••••••••••••••9.6

B.

MicroDr,y, Ultra.fine••••••••••••••••••••••••••••••••••38.5
Alcohol soluble aluminum chlorbydroJty allantoinate •••• 0.5

c.

Crodamul IPM•••••••••••••••••••••••••••••••••••••••••12.9
100.0

Phase A was

~issolved

at 70°C and B was added with constant

stirring until a uniform mixture resulted.
constant stirring until uniform.

C was added with

The mixture was poured into

2-gram suppository molds to cool.

Crodesta A 10, the

lipophilic gellant, provided excellent structure and slip
to a solid stick.

(

Crodamul IPM and Procetyl AWS served as

emollients and to reduce tackiness.

The latter was also

used to improve water dispersability of the antiperspirant
agent and act as a dispersing agent for the active ingredient upon application (113).

In order to provide a

smaller sample application size, a concentration of 38.5"fe
MicroDry, Ultrafine was necessary.

Thus, a solid stick of

260 mg imparted 100 mg of active ingredient.

The amount of

active ingredient was consistent with the other three dose
forms.
Rehydrol is often used by the industry as an antiperspirant agent in pump sprays, because it is effective,
quick-drying, and causes a minimum amount of tackiness.
It may be used in alcoholic or hydroalcoholic solutions.
Stearic acid is generally added to alcoholic solutions
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to prevent gellation and to lubricate the pump spray valve

(96).

However, to maintain allantoin complex compatibility,

a hydroalcoholic solution was needed.

So, to maintain

consistency in all the vehicles, Chlorhyd.rol,

50'~

w/w

solution was selected as the active ingredient in the
alcohol-base dose form.

Chlorhyd.rol is used in many

commercial hydroalcoholic solutions (95,96,98,99).

%,

weight

A.

Alcohol •••••••••••••••••••••••••••••••••••••••••••• 50.00
Arlamol E ........................... •·•• •·•·• .............. 5.00

B.

Chlorhydrol, 50'fo w/w solution •••••••••••••••••••••• 40.00
Alcohol soluble aluminum chlorbydroxy allantoinate •• 0.25
Water, distilled••••••••••••••••••••••••••••••••••••4.75
100.00

A and B were dissolved separately at room temperature. B
was added to A with constant agitation until dissolved.
Arlamol E functioned as a solvent, emollient, and valve
lubricant.

This clear hydroalcoholic test antiperspirant

imparted 100 mg of active ingredient per 500 mg of antiperspirant applied.

The solution was shown to be suitable

for use in a commercial manual pump spray.
Perfumes and coloring agents were not incorporated
into any of the antiperspirant formulations.

This

eliminated ·the possibility of allergic reactions,
dermatological irritations, physical and chemical
formulation incompatibilities, and other variables
associated with perfumes and coloring agents.

The
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volunteers preferred unscented commercial antiperspirants
for their daily use prior to the test.
Preservatives were deemed unnecessary because the
ingredients used in formulations are extremely stable.

These

formulations did not separate, cream, or show any other
instability or aging signs during their six-month shelf
life.

2.

Test procedure.

Four vehicles containing

aluminum chlorhydrate were compared for efficacy by a
well-recognized gravimetric procedure (4-6,9-12,23-27,

38,55,57) during a normal work day in each subject's
normal work environment.

(

A detailed report of the proposed project, its
objectives, methods, and potential adverse effects was
submitted for approval to both a University Human Studies
Committee and an Institutional Review Board (Appendix B).
Following the guidelines established by these committees,
volunteers were asked to maintain normal bathing habits
with the exception of an axillary hygiene regimen.

The

axillary hygiene regimen consisted of abstaining from
non-test antiperspirant/deodorant use during the test
period, removal of axillary hair with Surgex (a surgical
depilatory) three days prior to each sweat collection
period, and washing the axillary area with Ivory Soap
and water only.

Each subject was supplied with the necessary

materials by the researcher.

,
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•
Sweat was collected on tared adsorbent Webril pads

taped snugly to the axillae with Dermicel cloth hypoallergenic tape.
less cotton.

Webril pads are made o!

100'~

sort, lint-

They have no binder and have a pH of

7. They

are used frequently in surgical procedures, plate, press,
and camera work, and in gravimetric antiperspirant
tests

(6,12,~3,24,114).

A 4-ply Webril pad was sewn onto a

2-by-4-inch piece of Ziploc.

The Ziploc backing ensured the

retention of sweat on the pad and easy removal of tape without loss of padding.
and weighed.

Each pad was sealed in a Ziploc bag

All bags were labeled with the subject's

name and the axilla and date each pad was to be worn.

(

A detailed calendar o! the nine-week experimental
protocol and weekly reminders (Appendix C) were distributed to each subject to ensure proper compliance.

Six

female and two male volunteers, ages 18-34, followed the
test guidelines at their own homes and jobs after
receiving instructions from the investigator.

Subjects

were instructed to observe the area outlined by axillary
hair.

Determining the outline of this region was

important, because all future sweat collections and
antiperspirants applications were confined to it.

The

hairy portion of the axilla is the region in which both
apocrine and eccrine sweating occur.

In a survey of panel

and nonpanel persons, the surface area delineated by
axillary hair was found to be consistenti..
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The calendar was divided into weekly segments.

Day 1

of each week was Sunday; days 2, 3, 4, 5, 6, and ? were Monday,
Tuesday, Wednesday, Thursday, Friday, and Saturday,
respectively.

On day 4 of the first week, all subjects

began the axillary hygiene regimen.

On day 7, all subjects

removed axillary hair with Surgex, an effective surgical
depilatory that removes hair below the skin line (115).
Removal of a.Xillary hair is essential to provide a clean,
hairless area to collect sweat (9,23,27,36,55,103).
Pretest sweat collections began in week 2 on days 4,
5, and 6, using both axillae as controls.

At the start of

each pretest collection day, the subject washed both axillae

(

with Ivory Soap and water, and patted them dry.

The

appropriate pad, cotton side to the body, was taped snugly
over the clean, dry, delineated axillary area of each
axilla.

Each panelist secured the tape in a manner most

comfortable for him.
wide strips.

Most subjects cut the tape into 1"

The pads were worn throughout a normal day's

conditions and environment.

After a 10-hour collection

period, the tape was removed, and the pads were returned to
the designated Ziploc bag and sealed.

They were collected

by the investigator the following morning to be weighed.
The differe.n ce in weight of the tared Ziploc plus dry pad
and Ziploc plus pad following the 10-hour collection period
was recorded as the sweat collected.

The weight was ex-

pressed in milligrams to the nearest tenth of a milligram.

45
Pretest sweat data are listed in Table 2.
Pretest sweat ratios were then calculated as
Perspiration weight from Ri,ht ~illa • Perspiration Ratio
Perspiration weight from Le t axilla
and averaged (23).

Subjects were then paired by similar

right to left axillae perspiration ratios (PR).

A split

plot, 4 by 4, Latin Square experimental design (116,117)
was used to eliminate the possibility that a treated
heavy- or light-sweating axilla might affect the results.
One subject of each pair was treated on his heavy-sweating
axilla, while the other subject was treated on his lightsweating axilla.

For example the PR, 1.636 of subject

B4 D2 and 1.422 of subject B4 D1 , indicated both subjects
sweated more on their right sides. Subject B4 n2 •s
light-sweating or left axilla was chosen randomly as the
side to be treated for the duration of the test; therefore,
subject B4 D1 •s heavy-sweating or right axilla was treated.
Their opposite axillae were assigned as the control. At
no time during the test was any antiperspirant applied to
the control axillae.
Treatment sweat collections began during week 3.

Test

antiperspirants designated for the subject for that week
were supplied in tared sealed containers.

The two members

of a pair applied the same antiperspirant treatment during a
given week.

The four pairs applied different treatments

during a given week conforming to the Latin Square

TABLE 2
PRETEST SWEAT COLLIDTION DATA
USED FOR BLOCKING 4 BY 4, SPLIT PI.OT, LATIN SQUARE

Aver~

PR•

0.787

0.838

B1D2
(PR)

116.2
115.2
0.991

231.6
157.4
0.680

71.1
78.1
0.910

o.860

B2D1
(PR)

192.2
237.2
1.234

34.2
56.3
1.647

262.2
555.4
2.118

1.666

B2D2
(PR)

490.5
293.3
1.672

236.0
554.0
2.347

80.1
230.3
2.875

2.298

1257.4 1202.1
B3D1
(PR)
1.046

298.9
289.3
0.968

916.2
865.8
0.945

0.986

836.0
630.0
1.327

468.1
710.2
0.659

119.6
96.5
0.807

0.931

1742.2 1614.2
(PR)
1.079

1482.7 1255.6
1.181

781.1
1567.2
2.006

1.422

520.8
296.4
1.757

970.4
1375.6
1.418

918.2
1592.3
1.734

1.636

. B3D2
(PR)
B4D1

B4D2
(PR)

•

1.044

.
.
R .
PersEiration weight ri~ht axilla
PR • Perspiration atio • Perspiration weight le t axilla
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(23)
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design (Table 3).

The cream was applied directly to the

axilla from glassine paper.

The stick was applied manually.

The lotion and hydroalcoholic solution were applied with
tared cotton swabs.
designated

All antiperspirants were applied to the

~by-4*9inch

axillary area.

The antiperspirant

application area was larger than the pad area to assure
adequate antiperspirant protection in the collectionsi te (Appendix C).
The axillary hygiene regimen continued in week 3 on
days 1 and 2.

A measured amount of test antiperspirant was

applied to a clean, dry treated axilla.

Tb.is two-day

period was to accommodate the axilla to the antiperspirant
(19).

(

No sweat was collected.
On days

3, 4, and 5, antiperspirant was applied to the

treated axilla as directed.

An elapsed one-minute drying

time was allowed before taping the tared pads to the axilla.
A tared pad also was taped snugly to the clean, dry, control
axilla.

The subjects proceeded with their daily routines.

At the end of the 10-hour collection period, they removed the
tape and sealed the pads in the designated Ziploc.

The pads

and test antiperspirant containers were collected by the
investigator to be weighed for daily sweat weights and
amount of antiperspirant applied.
A nine-day period, in which no sweat was collected nor
antiperspirant was applied, was allowed for recovery.
)

axillary hygiene regimen was continued throughout the

The

TABLE 3

(

4 BY 4 1 SPLIT PI.OT, LATIN SQUARE DESIGN

B~1

(

A1

~

~

A4

A2

A3

A4

A1

A3

A4

A1

A2

A4

A1

~

~

A1

~

A3

A4

~

~

A4

A1

A3

A4

A1

A2

A4

A1

~

A3

A • Treatments:. 1, stick; 2, cream;
3, lotion; 4, hyd.roalcoholic base
B • Subject Pairs, 1, 2, 3, 4
C • Weeks, 1, 2, 3, 4
D • Side Treated: 1, heavy-sweating
side; 2, light-sweating side
48
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recovery weeks.

Recovery periods, weeks 4, 6, and 8,

alternated with treatment weeks 5,

?, and 9, using the

test procedure described above for the duration

or

the

experiment.

3.

Statistical treatment of results.

Post-test

sweat collection data were evaluated statistically using
the geometric mean of treatment results of a 4 by 4,
split plot, Latin Square design (26,116), illustrated in
Table 3.

The letters D1 and D2 represent the heavy-sweating
sides and light-sweating sides treated, respectively. The
columns represent the four treatment weeks, the rows represent subject pairs, and the blocks indicate the treatments.
The statistical model describing this treatment design is

(

+€

jkmp

where
Yjkmp • ln (ratio) • Ln ((mgtreated) - ln (~gcontrol)
.){ = overall mean

o<j • treatment j, j•1,2,3,4; ~"'-j • 0

$k

• subject k, k • 1,2,3,4; i~ k • 0

'{ m = week m, m • 1,2,3,4; i:. ~ m • 0

J

P • side p, p •1 , 2; ~ S p

°" S jp •
/j
(

S kp

=0

treatment and sides interaction jp.-NID

• subject and sides interaction kp ""NID

(o,o2 )

(o,d-; 2 )

50
(

g•mp • weeks and sides interaction mp ,...NID (o,~ 2 )
Ejkmp • error for treatment j, subject k, week m,
side pA-NID (O, <S 2)
The AO"V is illustrated in Table 4.
The sweat ratios were calculated as

where y •

pe~spiration

weight (mg) or the treates 8.ide :tand

x • perspiration weight (mg) of the control side.

The

post-test sweat ratios were transformed to natural
logarithms to simplify the calculations in the analysis of
variance table.

The F test indicated the absence or presence

of significant differences in the variables.
The ratio of treatment axilla to control axilla was
estimated by
A

ln Rj • Aj/8

the ref ore
Rj • e(Aj/8)
A

where Rj is the post-test treatment ratio mean.
The antilog or the geometric mean of the data from
each treatm,ent was calculated and subtracted from unity to
obtain the percent sweat reduction of each treatment.
A

(1 - Rj) x 100

= percent

sweat reduction.

Confidence intervals of 95 % about the treatment mean,

,,.--...

,,.--...._

,,.--...._

TABLE 4
ANALYSIS OF VARIANCE FOR 4 BY 4, SPLIT PLOT, LATIN . SQUARE

Source of Variation

VI
~

SS

DF

F Test

MS

Treatments (A)

3

2
2
{Aj /8 - G /32
j

SSA/3

MSA"error (A)

Subject Pairs (B)

3

l.~2/8 - G2/32

SSB/3

MSi1error (A)

Weeks (C)

3

{Cm
m

2
2
/8 - G /32

SS0/3

Sides (D)

1

2
tDP2/16 - G /32

k

• Ms

0/error (A)

SSif'1

MSif'error (B)

t~(BDkp) /4 - SSB - SSD - G /32

SSBnf3

MSniferror (B)

2
2
/4 - SSC - SSD - G /32

SSci/3

MSclf'error (B)

p

2

Subjects x Sides
(BD)

'

kp

Weeks x Sides
(CD)

3

~~(CD )
mp
mp

2

TABLE 4--Continued

Source of Variation
Treatments x Sides
(AD)

'"

I\)

Pooled Residual

DF

SS

t~(ADjp) 2/4 -

3

jp

12

{{((yjkmp
jkmp

2

F Teet

MS

2

SSA - SSD - G /32

SSAJY'3

MSAJY'error (B)

- SSA - S8a - SSC -

~
2
SSD - SSAD - SSan - SScn - G /32

SSAB'

6

~i(BC~/2 - SSA - S8a - ss0 - G2/32 error (A)

SSABD'

6

Pooled Residual - SSAB'

km

TOTAL

31

~l~ty'jkmp

jkmp

2

2

- G /32

error (B)

(
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A

Rj' were estimated by

(A)
( •j/S) ! t 6~;05~vf error
8
A

The upper and lower confidence limits were expressed in terms
of percent sweat reduction by

and
1
(1 - e ) x 100

where eu and e 1 a.re the antilogs of the upper and lower
confidence limits, respectively.

(

Having shown significant treatment differences with
the F test, the Least Significant Difference (LSD) test
was performed to make individual comparisons of differences
between pairs of treatments.

-

where xi' xj • treatment means.
2 (error (A))
8

(
IV.

DISCUSSION AND RESULTS

The tests were organized so that there was a two-week
abstinence from antiperspirant use before the treatment
sweat collections began.
perspirant

u~e

Subjects abstained from anti-

for one week before the three pretest sweat

collection readings were made.

Tb.ere was a one-week re-

covery period of no antiperspirant use between treatments.
Abstinence from antiperspirants ensured no carry-over effect
from previous antiperspirant use.

All eight subjects

collected sweat for three collection days per treatment.

(

All subjects were tested on all four treatments.
The F test (Table 5) indicates differences in
treatment effects, sides by subjects effects, and weeks
by sides effects.

No significant differences were found

in subjects, weeks, sides or treatments by sides.
It is of particular interest that the sides' (D)
F value was extremely low.

The pretest blocking pro-

cedure was instituted to account for the light- or heavysweating side treated, yet the results indicated that the
side which was treated could have been randomly selected
without regard to pretest sweat ratios.

This is in

agreement with Wooding and Finklestein's (26) decision to
eliminate pretest sweat ratios in evaluating antiperspirant
efficacy.

This result is further substantiated by the
~

(

TABLE 5
ANOVA OF POST-TEST DATA

DF

SS

Treatments (A)

3

Subject Pairs (B)

MS

F Value•

1.411

0.470

5.311

3

0.659

0.220

2.486

Weeks (C)

3

0.079

0.026

0.294

Sides (D)

1

0.004

0.004

0.125

3

1.002

0.334

10.438

Weeks x Sides
(CD)

3

0.616

0.205

6.406

Treatments x Sides

3

0.145

0.048

1.500

12

0.721

0.060

Source of Variations

(

-::Subjects __x~Sid.es

.

.!BD)

(AD)

Pooled Residual

TOTAL

SSAB'

6

0.531

0.0885 (error (A))

SSABD'

6

0.190

0.0320 (error (B))

31

4.637

•where F3 , 6 ,. 05 • 4.76
..
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insignificant F value of subject pairs (B). Subjects were
paired by similar pretest treatment ratios.

One subject

was treated on his heavy-sweating side, while his paired
opposite was treated on his light-sweating side.

Supject

pair 3 had pretest sweat ratios very close to unity
(Table 2) in which case it was an arbitrary decision to
call a side light- or heavy-sweating.

Treatment by sides

effects (AD) .. indicates that the side to which the treatment
is applied is not significant.
However, the F value indicates a strong subjects by
sides (BD) effect.

Figure 3 gives an indication of why

this difference occurred.

By plotting the light side to

heavy side pretest sweat ratio average of each subject pair 1
versus the sum of the treatment ratios' natural logarithms
of each subject by side (BD), the cause of the interaction
is readily observable.

All subject pairs exhibited

similar sides by subjects effects, except subject pair 3.
This interaction is of particular interest because they had
pretest sweat ratios close to unity.

Their daily pretest

sweat ratios showed extreme day-to-day variations, but
averaged close to unity.

Steed (9) also observed marked

variations in subjects with pretest ratios close to unity.
Otherwise, .the other three subject pairs had no difference
in this effect.
As expected, there was no significant difference in
treatment weeks effects (C).

During each of the four
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1.0

x Heavy-sweating side treated
• Light-sweating side treated

•

o.o

-1.0

-2.0

L/H
B

0.5
2

0.7

0.6
4

0.9

0.8

1.0

1

Figure 3. The pretest sweat ratios of lightsweating side to heavy-sweating side (L/H)·
of Subject Pairs (B) versus Subjects by
Sides (!\(BDkp)) illustrates the Subjects
by Sides interaction occurs in Subject Pair 3.
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treatment weeks, all four treatments were tested, with each
subject pair testing a different treatment in a given week,
and no pair testing the same treatment in the same week.
There was no major change in the sum o! the ratio's natural
logarithms for each treatment week

(~Cm)'

despite the fact

that during the first three treatment weeks the average
environmental temperature was in the low 60sfF .: and the
average relative humidity was 40}6, while in treatment week
4, the average temperature was in the high
average rel ative humidity was

?Cf),

(118).

?Os~F '

and the

Most subjects

were wearing lightweight sweaters during this period and
working indoors.

(

However, weeks by sides (CD) exhibited

a significant difference.

Figure 4. plots the treatment

week versus the sum of each treatment week by side
(~tCDmp).

Heavy- versus light-side treatment shows a

major change during week 3.

Since this does not appear

to be due to environmental factors, it may well have been
caused by emotional factors.

Treatment week ;, May ?,

occurred during the last week o! classes or examination
periods for the subjects, who were all in academic
surroundings.

There was a great deal of pressure on the

subjects to finish course work and write exams.
sweating

h~s

Emotional

been suggested as a cause of erratic sweat

ratios and rates (57,58).

However, it did not affect the

antiperspirants' effectiveness.

All subjects participated

in muscular exercise, such as tennis, jogging, or dancing,
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1.0

x • Heavy-sweating side treade
• • Light-sweating side treate

o.o

•

-1.0

x

-2.0

c
Week of

1

4-9-78

2

4-23-78

3

4

5-7-78

5-21-78

Average RH (%)

40

30

50

70

Average T (°F)

50s

60s

60s

70s

Figure 4. The effect of Weeks (C) versus Weeks by
Sides (it(CDmp)) indicates an interaction during
Week 3, a possible result of emotional stress
on sweating. The average relative humidity (RH)
and temperature (T) did not markedly affect
- s weating ratios.

(
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at various ti.mes.

This activity was noticeable in daily

sweat collection weights, but not in overall sweat ratios •
.Antiperspirant effectiveness was maintained during exercise.
A significant difference in treatments was caused by
the stick antiperspirant.

The natural logarithms of the

treatment means (ln Rj) in Table 6 showed a marked
difference in treatment 1's mean compared to the other
three treatment means.

This is verified by the LSD test.

However, no significant difference was found among treatments 2, 3, and 4.
Percent sweat reduction results in decreasing order
of antiperspirant effectiveness response are treatments 3

(

(lotion, 38.CJ'h), 4 (hydroalcoholic solution, 32.4%),
2 (cream, 31.8%), and 1 (stick,

~6.2°fe).

Percent sweat

reductions and their confidence intervals are shown in
Table 6.

The wide confidence intervals, a result of a

low degree of freedom and high standard deviation
(error (A)), are not uncommon in antiperspirant efficacy
testing at normal temperatures (9,57).

However, percent

sweat reduction results of the treatments containing
Chlorhydrol, 50% w/w solution, agreed with previous studies
(4,9,19,96,108).
duction averaged

'lb.e previ ous studies showed sweat re30-4ry;~ ,

regardless of concentrations of

antiperspirant agent applied.

Table 6 lists the average

dose of active antiperspirant agent applied.

It is curious

to note that the lotion with the lowest dose applied obtained

,,,.--..._

"""""'

TABLE 6
ANTIPERSPIRANT TREATMENT EFFICACY AND DOSAGE

Treatment a
(})
....l.

in

Rj b

Percent
Sweat
Reduction

(%)

Confidence
Intervals,
95%

Average
Treatment
Applied

(%)

(mg)

Average Dose
Active Agent
Applied
(mg)

A1

0.060

-6.2

-37.3 to 17.9

143.04

69.16

~

-0~382

31.8

11.8 to 47.2

379.96

75.99

A3

-0.478

38.0

19.8 to 52.0

172.76

34.55

A4

-0.391

32.4

12.5 to 47.7

263.52

52.70

aA1 , stick; ~' cream; A , lotion; A4 , hydroalcoholic solution.
3
bRatio of treated axilla to control axilla estimated by ln Rj • Aj/8.
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the best antiperspirant efficacy results, while the stick
with a high dose of active ingredient applied increased
sweating on the treated side.

Subjects generally applied

the same amount of a given antiperspirant during the
treatment week.

Individual subjects tended also to be

consistent in the application of a small or large amount
of antiperspirant throughout the test.

Since subjects

applied the treatments themselves, this may be a result of
personal preference for commercial antiperspirant quantities
used routinely before engaging in this experiment.
Personal acceptance of a product frequently plays an
important role in the effectiveness of a product (11,64,96).

(

The lotion was considered the most cosmetically acceptable
and elegant dose form by all subjects, while the stick form
brought many complaints.

The subjects used commercial

aerosols or roll-on antiperspirant/deodorant products
prior to testing.

None of the subjects had ever used a

stick or cream-based antiperspirant before.

This may also

have influenced their acceptance or rejection of the
vehicles.
A small scale test was conducted by one subject using
only the stick vehicle minus the active ingredient.

This

subject followed the same protocol used during the test
weeks.

The average sweat ratio was close to unity.

ratios also were close to unity.

Daily

Since the subject's

heavy-sweating side was treated and a decrease in sweat on
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the treated side was observed, the base was ruled out as a
properspirant.

Of course, ratios close to unity, as noted

previously in subject pair ;, produced erratic results.
Increased sweat ratios with the stick formulation may have
been caused by the antiperspirant agent being suspended in
the vehicle coupled with difficulty in application.
The antiperspirant agent was in suspension in the stick
formula, rather than in solution as in the other three
treatments (95-97).

The activity of MicroDry, Ultrafine

was dependent on the dispersing agent, Procetyl AWS.

The

activity of topically applied drugs is often influenced by
their release rates of drugs from the carrier vehicle (1-10,

(

91).
The incorporation of MicroDry, Ultrafine into the
stick base resulted in a hardening, caused by the
suspension and the dry, impalpable powder in the base, so
that the product was heavier and more difficult to apply
than the vehicle alone.
Day-to-day sweat ratios vary, although the heavysweating side usually remains the same.

It is of

particular interest to note that, when the same amount of
active ingredient was applied to a given subject during a
given treatment week, the sweat ratios still varied from
day-to-day, but did not affect overall antiperspirant
efficacy.

This daily fluctuation in sweat ratios was the

reason for considering all collection data, regardless
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of a day of light or heavy sweating.

Sweat collection data

of all participants were used whether they sweat profusely
or sparingly.

These data reflect a normal population

that makes use of antiperspirants in the daily environment.
The effect of dominant-handedness on sweat ratios could
not be assessed conclusively.

Of eight subjects, four

sweat more on the right axilla, but one of these four was
left-handed. · Two subjects had sweat ratios close to unity.
Their heavy-sweating sides were on the left.
subjects were right-handed.

Both these

Of the two subjects with a

heavier sweating left axilla, one was right-handed and the
other was left-handed.

(

The males, who removed their axillary hair for the
first time, noted a marked decrease in: axillary odor (36,3S,

54,55) and developed an immediate dermatitis-like reaction
following the first application of Surgex.

Tb.is reaction

disappeared within 24 hours without medical treatment.
did not recur in subsequent applications.
not complain of irritation from Surgex.

It

The females did
The daily sweat

volume of the majority of females was greater than that of
the two male subjects.
Aside from discomforture experienced with the stick
form, no

co~plaints

of irritation from antiperspirant test

products were recorded.

The incorporation of allantoin

complex in combination with aluminum chlorhydrate was
apparently beneficial in reducing antiperspirant irritant
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(

potential and enhancing cosmetic qualities of the dose form.
However, the use of the cloth hypoallergenic tape became
uncomfortable by the third collection day.
apJPSar to affect sweat weights or ratios.

This did not
Exercise and

emotional stress had the greatest effect on sweat weights.
Future Studies
1.

Antiperspirant efficacy could be tested in

individuals who exhibit sweat ratios close to unity.

The

same test could be conducted on subject pair 3 with reversed sides treated to see if the same interaction would
occur and how unity ratios affect sweating.
2.

(

Studies could be designed to test varying

concentrations of the same agents in the same vehicle and
in different vehicles.

3.

A detailed study could be conducted of anti-

perspirant release rates from various vehicles, especially
a solution versus a suspension.

Further studies are needed

of the stick vehicle only compared to the stick antiperspirant and how individual vehicular components affect
the active
4.

ingredient~s

release rate.

This study could be repeated exactly as presented

here, using the same subjects and having them each apply
identical amounts of active ingredient to the axilla, then
comparing results in ordinary and controlled environments.

(
V.
1.

CONCLUSIONS

It is concluded that vehicle does not affect

antiperspirant efficacy.
2.

However, release rate of the active ingredient from

the vehicle plays an important role in antiperspirant
efficacy, as observed with aluminum chlorhydrate in solution
in the cream base, aqueous lotion, and hydroalcoholic base
versus aluminum chlorhydrate in suspension in the solid
stick.

3.

(

Antiperspirant treatment response in terms of

percent sweat reduction (in decreasing order of effectiveness)
was:

lotion, 38.0'%; hydroalcoholic solution, 32.4%; cream,

31.SC/o, and stick, -6.2'/o.

The gravimetric testing pro-

cedure conducted during a normal work day in each subject's
normal work environment produced percent sweat reduction
results well within the acceptable antiperspirant
efficiency ranges.
4.

The 4 by 4, split plot, Latin Square experimental

design was statistically satisfactory.

Statistical analysis

indicated that the side treated may be selected randomly
without compromising the results.

5.

Sweat weights may be affected by temperature,

muscular exercise, or emotional stress.

However, these

factors did not affect antiperspirant efficiency.
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VI.

APPENDICES

APPENDIX A
Several preliminary formulations were tested and
compared for physical and chemical compatibility,
stability, and cosmetic elegance and acceptability.
Physical and chemical compatibility results led to the
selection of aluminum chlorhydrate over modified aluminum
chlorhydroxy allantoinate as the active agent.

Aluminum

chlorhydroxy allantoinate in concentrations of 0.25% was

(

added to formulations containing aluminum chlorhydrate for
its therapeutic and cosmetic properties.

The formulations

listed below are examples of preliminary formulations tested.
Several additional preparations based on the listed
formulas were formulated by varying the concentrations of
cert ~ in

component ingredients to aid in the selection of

the test antiperspirant products.
The following product is an example of a basic
oil-in-water emulsion (90).

It was a

well~textured

however, it was stiff and dry on application.

cream;

A.

%, weight
Stearic Acid ••••••••••••••••••••••••••••••• 15.0
Arlacel 60 •••••••••••••••••••••••••••••••••• 5.0
Tween 60 SD ••••••••••••••••••••••••••••••••• 5.0

B.

Distilled water •••••••••••••••••••••••••••• 55.0
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o.

Aluminum chlorhydroxy
• allantoinate modified •••••••••••••••••••• 20.0
100.0

Preparation: Heat A and B separately to 85°0. Add B
to A with constant agitation until cooled to 45°0. Add
C. Stir until a smooth mixture is formed.
This product (90) was a smooth, homogenous, fluffy,
cosmetically appealing cream.

It deposited a fine,

white, quick-drying film upon application.
A.

%, weight
Sodium lauryl sulfate •••••••••••••••••••••• 2.00
Distilled water ••••••••••••••••••••••••••• 15.00

B.

Titanium dioxide ••••••••••••••••••••••••••• 0.25

O.

Aluminum chlorhydroxy
allantoinate modified ••••••••••••••••••• 15.00
Distilled water ••••••••••••••••••••••••••• 42.75

D.

Spermaceti ••••••••••••••••••••••••••••••••• 3.00
Glyceryl monostearate ••••••••••••••••••••• 16.00

(

Myri 52••••••••••••••••••••••••••••••••••••6.00

100.00
Preparation: Stir A until dissolved. Suspend B in
A, warm to 70°0. Stir 0. until dissolved and warm to
70°0. Heat D slowly with constant agitation to 65°0.
Run D into mixture AB while stirring. Slowly add 0 at
60°0. Stir constantly to 40°0.
This stiff, cosmetically undersirable cream
contained
A.

%, weight
Amerchol L-101 ••••••••••••••••••••••••••••• 3.00
Modulan •••••••••••••••••••••••••••••••••••• 2.00
Spermaceti ••••••••••••••••••••••••••••••••• 4.00
G-2162•••••••••••••••••••••••••••••••••••••2.00
Myrj 5.2••••••••••••••••••••••••••••••••••••2.00

Glyceryl monostearate ••••••••••••••••••••• 17.00

B.

Propylene glycol ••••••••••••••••••••••••••• 3.00
Distilled water ••••••••••••••••••••••••••• 27.75
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C.

Chlorhydrol, 50'fe w/w solution ••••••••••••• 38.00
Aluminum chlorhydroxy allantoinate ••••••••• 0.25
Titanium dioxide ••••••••••••••••••••••••••• 1.00
100.00

Preparation: Heat A and B separately with constant
stirring to 85°C. Add B to A slowly, stirring
constantly to 40°C. Add C to mixture and stir to 35°C.
A cosmetically elegant cream that was easy to apply
was formulated (94).

However, the desirability of limiting

the number of component ingredients in the test procedure
eliminated this formula.

(

%, weight

A.

Veegum.•••••••••••••••••••••••••••••••••••••2.00

B.

Amerchol L-101•••••••••••••••••••••••••••••5.00
Solulan 98•••••••••••••••••••••••••••••••••1.00
Ce~yl alcohol •••••••••••••••••••••••••••••• 1.00
Arlacel 165••••••••••••••••••••••••••••••••7.00

C.

Chlorhydrol, 50 % w/w solution •••••••••••• 40.00
Aluminum chlorhydroxy allantoinate ••••••••• 0.25
Glycine •••••••••••••••••••••••••••••••••••• 2.00

Distilled water ••••••••••••••••••••••••••• 41.75

100.00
Preparation: Add Veegum to water slowly, agitating until
smooth. Heat to 80°C. Heat B to 70°C. Add B and A
stirring constantly. Cool to 35°C. Mix C at room
temperature until a clear solution is formed. Add C to
mixture AB. Continue stirring until a smooth,
homogeneous cream is formed.
An extremely viscous oil-in-water lotion emulsion

was prepared (94).

The consistency was suitable for

roll-on applic ation; however, a simple aqueous lotion
was preferred as a test vehicle.

A.

%, weight
Amerchol L-101 ••••••••••••••••••••••••••••• 5.00
Solutan 98 ••••••.••.•......••...•••.••.•••• 2.00
Cetyl alcohol •••••••••••••••••••••••••••••• 1.00
Arlacel 165 ••••••••••••••••••••••••••••••• ~4.00
Glycerine •••••••••••••••••••••••••••••••••• 2.00
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(

B.

c.

Veegum•••••••••••••••••••••••••••••••••••••o.50

Distilled water ••••••••••••••••••••••••••• 49.25

Chlorhydrol, 5CYJ~ w/w solution ••••••••••••• 36.00
Aluminum chlorhydroxy allantoinate ••••••••• 0.25
100.00

Preparation: Disperse Veegum thoroughly in ·-water at ·Doam
temperature. Heat to 90°C and hold at this temperature
vhile stirring for one hour. Heat A to 80°C. Add B to
A slowly with constant stirring. Stir to 40°C. Add c.
Continue stirring to 35°C.
The following two formulas (99) are examples of the
solubility difficulties encountered in preparing an
alcohol-based antiperspirant with the alcohol soluble

(

form of modified aluminum chlorhydroxy allantoinate.
%, weight
A. Alcohol soluble aluminum chlorhydroxy
allantoinate modified ••••••••••••••••••• 20.0
Stearic acid •••••••••••••••••••••••••••••.•• 2.0
Ethanol, 959b •••••••••••••••••••••••••••••• 76. 0
B.

Arlamol E •••••••••••••••••••••••••••••••••• 2.0

100.0
Preparation: Dissolve A at room temperature.
stirring until a clear solution is formed.
A.
B.

Add B,

%, weight
Ethanol, 95% •••••••••••••••••••••••••••••• 70.0
Arlamol E•••••••••••••••••••••••••••••••••• 5.0
Alcohol soluble aluminum chlorhydroxy
allantoinate modified ••••••••••••••••••• 20.0
~istilled water••••••••••••••••••••••••••••5.0

Preparation: Stir A at room temperature until a clear
solution is formed. Slowly add B and stir until clear.
This quick-drying, nontacky solution was formulated
employing a concentration of Rehydrol equivalent to doses
af

aluminum chlorhydrate in the test products (99).
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(

%, weight
A.

Rehydrol••••••••••••••••••••••••••••••••••26.70
Ethanol, 95%••••••••••••••••••••••••••••••46.30

B.

Distilled water ••••••••••••••••••••••••••• 24.75
Alcohol soluble aluminum chlorhydroxy
allantoinate ••••••••••••••••••••••••••••• 0.25

C.

Arlamol E •••••••••••••••••••••••••••••••••• 2.00

100.00
Preparation: Dissolve separately A and B.
A. Stir until a clear solution is formed.
Stir until clear.

Add C to
Add B.

The acidic aluminum salts are not suitable for use in
a sodium stearate-based stick.

Bodium aluminum chlorhydroxy

lactate, forms a cosmetically acceptable, yet ineffective
soap-based antiperspirant stick.

(

The neutral gelling

agent, Crodesta A 10, produces a stick of suitable
consistency.

The addition of silicone fluid reduces

tackiness and enhances stick slip and structure.
However, the following formula (97) crumbled upon
appl ication.

A.

%, weight
Crodesta A 10 ••••••••••••••••••••••••••••• 28.00
Procetyl AWS •••••••••••••••••••••••••••••• 10.00

B.

Rehydrol •••••••••••••••••••••••••••••••••.• 20.00
Alcohol soluble aluminum chlorhydroxy
allantoinate ••••••••••••••••••••••••••••• 0.25

c.

Silicone Fluid 200, 1000cps ••••••••••••••• 41.75
100.00

Preparation: Heat A to 65°C. Add B. Stir Wltil
Wliform. Add C. Stir until smooth. Pour into 2-gram
suppository molds to cool.
The following water-in-oil emulsion stick (97)

?2

(

was cosmetically unacceptable.
upon application.

The stick was dry and tacky

The excessive number of component

ingredients, and the emulsion base, were additional
reasons to
A.

eliminate ~

this product.

%, weight

Veegum ••••••••••••••••••••••••••••••••••••• 1.00

Distilled water ••••••••••••••••••••••••••• 29.75
MicroDry, Ultrafine ••••••••••••••••••••••• 20.00
Aluminum chlorhydroxy allantoinate ••••••••• 0.25
B.

Super Hartolan•••••••••••••••••••••••••••••2.00
Amerchol . L-101 •••••••••••••••••••••••••••• 10.00
Amerchol CAB ••••••••••••••••••••••••••••••• 4.00
Stearic Acid •••••••••••••••••••••••••••••• 16.00
Paraffin ••••••••••••••••••••••••••••••••••• 3.00

Silicone Fluid 200, 1000 cps ••••••••••••••• 3.00
Propylene glycol •••••••••••••••••••••••••• 10.00
Arlacel 186••••••••••••••••••••••••••••••••1.00
100.00

(

Preparation: Disperse the Veegum in water. Add
the MicroDry and allantoin complex. Heat A with
constant stirring to 85°C. Heat B with constant
stirring to 85°C. Add A to B and blend until smooth.
Pour into 2-gram suppository molds to cool.
The stick antiperspirant formula was adapted from
a lipstick base.

The stick's consistency was cosmetically

undesirable.for antiperspirant application .(92).
%, weight
A. Ozokerite •••••••••••••••••••••••••••••••••• 6.00
Carnauba wax, yellow #1 •••••••••••••••••••• 4.00
Candelilla wax•••••••••••••••••••••••••••••8.00
Propylene glycol •••••••••••••••••••••••••• 51.35
Tenex BHT •••••••••••••••••••••••••••••••••• 0.10

B.

c.

Crodamul IPM •••••••••••••••••••••••••••••• 10.30
MicroDry, Ultrafine ••••••••••••••••••••••• 20.00
Aluminum chlorhydroxy allantoinate ••••••••• 0.25
100.00

Preparation: Heat A to 90°C with constant stirring. Add B,
stirring until smooth. Add C, stirring until smooth. Pour
into 2-gram suppository molds to cool.

APPENDIX B
Experimental Protocol
The Effect of Vehicle on Antiperspirant Efficacy
College of Pharmacy, University of Rhode Island, 1978
Investigators:

M. H. Smith, B.S.
Graduate Student

J. M. Lausier, Ph.D.
Associate Professor, Department of Pharmacy

G. E. Osborne, Ph.D.
Professor, Department of Pharmacy

(

C. T. Rhodes, Ph.D.
Chairman and Professor, Department of Pharmacy

C. I. Sn).ith, Ph.D.

Chairman and Professor, Department of Medicinal Chemistry
Objectives:

This study is concerned with how

vehicular excipients in an antiperspirant formulation affect
the efficacy of the product.

Using a single, proven antiper-

spirant entity in different vehicles, we shall examine the
effect of those vehicles on the efficacy of typical cosmetic
products.

A roll-on lotion, a cream base, a solid stick,

and an alcohol base such as one used in the manual pump
spray will be formulated and evaluated gravimetrically for
the influence of vehicle on antiperspirant efficiency.
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Preliminary Screening of Subjects:

Subjects con-

sidered for this study will be heal tbT.",'pers.ons··nth· ·n o bro·k en
or irritated axillary skin and no sensitivities to Aluminum
Chlorhydrate, Aluminum Chlorhydro:xy Allantoinate, or
thioglycollates.

Subjects will undergo sample patch tests

several days prior to testing to check for sensitivities,
toxicity, and irritation that may result from the antiperspirant products or the hair-remover cream.

Any medical

or cosmetic abnormality which the investigators believe may
be likely to complicate the study will exclude the subject.
All subjects will be interviewed carefully and
pertinent medical, especially dermatological, information
will be gathered.

(

Investigators will explain the informed

consent form to all participants.

All participants will

have read the informed consent form before they will be
allowed to sign it.
the investigators.

Participants will be able to question
Any subjects may withdraw from the study

at any time during the investigation.
Participants will be required to abstain from non-test
antiperspirant/deodorant use during the test period, remove
axillary hair with a surgical depilatory at designated
intervals during the test period, and wash the axillary area
with Ivory Soap and water only.
The test will be conducted during a normal work day
for 10 hours in the subject's normal work environment.
Results will be evaluated statistically using a gravimetric
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technique.
~ach subject will be supplied with Surgex, a

hair-remover cream, Ivory Soap, tared adsorbent pads in
sealed plastic bags, and antiperspirant products to be
tested.
The subject will be requested to maintain normal
bathing habits throughout the test period with the exception of the axillary hygiene regimen.

The axillary

hygiene regimen consists of washing the axillary region
with Ivory Soap and water only, patting the area dry, and
removing axillary hair at designated intervals during the
test period.

(

Only products supplied by the investigators

may be used under the axillary region.
Sweat will be collected on tared absorbent pads
taped snugly to the axillae with hypoallergenic tape.

A

treated and control axilla (e.g., right axilla treated with
left axilla as control) will be assigned to each subject and
the treated and control axillae will remain the same throughout the test period.

At no time should any antiperspirant

be applied to the control axilla during the test period.
Experimental Prodedure Calendar:
divided into weekly segments.

The calendar is

Day 1 of each week is Sunday,

day 2 is Monday • • • day 7 is Saturday.
Week 1:

Day 4 (Wednesday) begin axillary hygiene

regimen as described above.

(

antiperspirant.

Discontinue the use of present

Day 5-6-7 continue axillary hygiene regimen.

(

?6

Day ? use Surgex on both axillae as directed.
Week 2:

Day 1 continue axillary hygiene regimen.

Day 2-3 continue axillary hygiene regimen. Day 4-5-6 pretest
sweat collection period begins using both axillae as controls.
Tape the tared adsorbent pad snugly to a clean, dry axilla.
Proceed with your normal daily work or routine.

At the end

of the allotted time period, remove the tape and place the
tared adsorbent pad in the designated plastic bag and seal.
These materials will be collected by the investigators.
Day 7 continue axillary hygiene regimen, but no sweat will
be collected.

Use Surgex on both axillae as directed.

Week 3:

(

Day 1-2 continue axillary hygiene regimen.

Apply test antiperspirant to premeasured area under clean,
dry treated axilla.

0ontrol axilla should be washed with

Ivory Soap and water only and patted dry.

This two-day

period is to accommodate the axillae to the antiperspirant.
No sweat will be collected.

Day 3-4-5 apply test anti-

perspirant to premeasured area under clean, dry treated
axilla.

Wait one minute for antiperspirant to dry, then

tape tared a(i.sorbent pad snugly to the axilla.

Tape a

tared aasorbent pad snugly to the clean, dry control axilla.
Proceed with daily routine.

At the end of the allotted

time period., remove the tape, and store the pads in the
designated plastic bags and seal.
collected by the investigators.
week 3, day 1-2.

These materials will be
Day

6-7 proceed as in
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Week 4:

Day

7 remove axillary hair with Surgex as

directed on package insert.
regimen.

Day

Continue axillary hygiene

1-7 is a recovery period. Continue with

axillary hygiene regimen.

No sweat will be collected and no

test or non-test antiperspirants will be used.
Week 5:

Testing of a second antiperspirant begins.

Proceed as in week 3.
Week 6:
Surgex on day
Week 7:

Recovery period.

Proceed as in week 4.

Apply

7.
Testing of a third antiperspirant begins.

Proceed as in week 3.
Week 8:· Recovery period Proceed as in week 4.
Apply Surgex on day
Week 9:

Testing of a fourth antiperspirant begins.

Proceed as in week
Note:

7.

3. Day 7 is end of testing.

Effective antiperspirant concentrations of

Aluminum Chlorhydrate range from 20 to 40 percent in the
vehicles being tested.
at these concentrations.

No adverse effects have been reported
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Informed Consent Form
The Effect of Vehicle on .Antiperspirant Efficacy
College of Pharmacy, University of Rhode Island, 1978
Investigators:
M. H. Smith, B.S.
Graduate Student
J. M. Lausier, Ph.D.
Associate Professor, Department of Pharmacy

G. E. Osborne, Ph.D.
Professor, Department of Pharmacy

c.

T. Rhodes, Ph.D.
Chairman and Professor, Department of Pharmacy

(

C. I. Smith, Ph.D.
Chairman and Professor, Department of 11edicinal Chemistry
Aluminum Chlorhydrate is an effective antiperspirant
agent used to reduce perspiration.

It is supplied normally

to the consumer as the active ingredient in antiperspirant
roll-on lotions, creams, solid sticks, aerosols, and manual
pump sprays, which are applied topically to the axillae as
needed to reduce perspiration and body odor.
The objective of this research project is to formulate
typical antiperspirant products in cosmetically acceptable
finished forms and evaluate gravimetrically the influence
of the vehicles on antiperspirant efficiency.
Should you volunteer to participate in the project,
you will be required to abstain from non-test antiperspirant/
deodorant use during the test period, remove axillary hair
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at designated intervals during the test period, and wash the
axillary area with Ivory Soap and water only.
You must have no broken axillary skin or sensitivities
to Aluminum Chlorhydrate, Aluminum Chlorhydroxy- Allantoinate,
or thioglycollates.

All necessary test materials will be

prepared and supplied by the investigators.

The anti-

perspirant products will contain effective levels of
Aluminum Chlorhydrate in a roll-on lotion, a cream base,
a solid stick, and an alcohol base ( such as one used
in the manual pump

sprcS."f1~

The safety and efficacy of

Aluminum Chlorhydrate as an antiperspirant are well
established; it causes no damage to fabric.

To

minimize or eliminate sensitivity reactions and irritation

(

to the axillary region, concentrations of 0.25% Aluminum
Chlorhydroxy Allantoinate will be incorporated into the
antiperspirant products.

Aluminum Chlorhydroxy

Allantoinate combines the astringent bacteriostatic properties
of Aluminum Chlorhydrate and the sustained healing activity
of allantoins.

It has proven to be non-toxic, non-irri-

tating, and even healing to irritated axillae.
To eliminate the irritation and broken skin
associated with shaving of axillary hair, a safe and
effective surgical depilatory, Surgex, will be used to
remove axillary hair.

It should not be applied to the

axillae within 48 hours of shaving.
Local skin irritation or sensitization at the site of
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(

application is one possible effect of the depilatory and/or
antiperspirant products.

As a volunteer for this project,

you may withdraw from it at any time during the investigation.

You will not be identified in any publication

resulting from this work.

I,

~~~~~--~~----------

, after reading and

understanding the above and having the opportunity to ask
questions regarding the above project now give my informed
consent for participation in the antiperspirant vehicle
evaluation project, University of Rhode 1 sland.

(

Witness

Date of Birth

------~----------------

-----------------

APPENDIX C
This appendix contains a sample nine-week
experimental protocol calendar and weekly reminders
distributed to the volunteers during this study.

All the

volunteers followed the test guidelines at their own
homes and jobs after receiving instructions from the
investigator.

Distribution of these materials was

well-accepted by the subjects as an aid in complying
with the experimental protocol.
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ANTIPERSPIRANT EXPERIMENTAL PROTOCOL
CALENDAR

Week

Day

1
SUNDAY

2

MONDAY

4
3
5
TUESDAY WEDNESDAY THURSDAY

6
FRIDAY

7

SATURDAY

())
I\)

BEGIN

1

SURGEX

March~

3
AP T #1

March _31 J\pril 1
SURGEX

Swea ~ Collecti pn Pads

2

PRETEST

March _2_0

Al?_ril 2

AP T #1
AJ?_ril ~

Al?_ril _2_

Al?_ril 4

AP T #1
Al?_l'il 10

Swea t Collecti pn Pads
T/C
T/C
T/C
AP T #1 AP T #1
AP T #1
A~ril 11 A.E_ril 12
A~ril 13

1\I>_ri 1

_2_

1\I>_ril 6

AJ;>_ril 2

Al?_ril 8

A_p_ril 14 A_E_ril 15

,......_

~-

CALENDAR--continued
Day

CX>

\)I

2
MONDAY

1

SUNDAY

Week

4

3
TUESDAY

WEDNESDAY oorfu,DAY

I

I

I

I
Swe

AP T #2

I SURGEX

I

4

Recovery

5

6
I FRIDAY
ISArfrRDAY

I

I

I

A ril 21 A ril 22

Collect· n Pads

AP T #2 I AP T #2

SURGEX

6

Recovery
Ma:v 2

4

M

6

,--....

,,--.

CALENDAR~continued

Day

Week

7

AP T

#3

2

1

SUNDAY

AP T

#3 I

Ma:

MONDAY

AP T

#3 I

Ma:v 8

3
TUESDAY

I WEDNESDAY
4
ITHURSDAY
5
I FRIDAY
6
I SATURDAY
7

swelt co11ectirn Pads
T/C
TIC

T/C
AP T

#3

AP T

#3

AP T

#3

Mav 11

M

Ma:v 12 I M

SURGEX

8

Recovery
Mav 14

~
9

APT #4

IMPORTANT:

20

16

T/C
APT#41

APT#41

Mav 21

Mav 22

swelt co11ectirn Pads
T/C
T/C

APT#4

APT#4
24

APT#4

26

Continue axillary hygiene regimen with Ivory Soap throughout the test
period. Apply collection pads to a clean, dry axilla.

AP T #, antiperspirant treatment number

T/C, apply antiperspirant treatment to TREATED AXILLA, apply pads to both axillae

85

(

Reminder Antiperspirant Volunteers
Week 2
On Saturday, April 1, 1978, use Surgex under both
axillae.
On Sunday, April 2, 1978, and Monday, April 3, 1978,
continue with Ivory soap regimen.
On

Tuesday, April 4, 1978, collect sweat with pad

provided for . 10 hours.

Be sure to apply the pad marked

Right Axilla to the RIGHT underarm area and the pad marked
Left Axilla to the LEFT underarm area.
hypoallergenic tape is provided.
side of the pad against the skin.
plastic covered side.

(

axilla.

Dermicel Cloth

Place the soft cotton
Place the tape to the

Tape pad suugly to appropriate

At the end of the 10-hour period, place the pad

under the RIGHT axilla in the bag marked Right Axilla.
Be sure to squeeze all the air out of the bag before
sealing.

Seal the bag securely.

Axilla pad.

Do the same with the Left

Bring the 2 marked bags in the following

morning.
On Wednesday, April 5, 1978, collect sweat for 10
hours with pads provided.

Apply pads as indicated in

Tuesday's procedure.
On Thursday, April 6, 1978, collect sweat for 10
hours.

Apply pads as indicated in Tuesday's procedure.
On Friday, April 7, 1978, continue Ivory Soap

regimen.
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On Saturday, April 8, 19?8, use Surgex under both
axillae.
NOTE:

The Ivory Soap regimen should be continued

throughout the test period.

(

(
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N.AME_ _ _ _ _ _ _ _ _ _ _ _WEEK

Your TREATED side is the

# _ _3_ _AP

--- axilla.

TRT #_1_ _

The test

-

CREAM antiperspirant is to be applied to this a.xilla ONLY.
Your CONTROL side is the

a.xilla.

NO anti-

perspirant should be applied to this axilla.
REMINDER:

CONTINUE WASHING BOTH AXILLAE WITH IVORY SO.AP AND

WATER ONLY FOR THE DURATION OF THE EXPERIMENT.
Application of the test CREAM antiperspirant (ap).
Note the area outlined by axillary hair under your
TREATED axilla.

Make a rectangle of this area.

area to which the ap will be applied.

This is the

Apply the ap provided

for the assigned day to the clean, dry TREATED axilla ONLY.

(

The cream ap should be rubbed on the axilla with the
glassine wrap.

Try to use the entire sample.

about 1 minute.

Allow to dry

Return the glassine wrap with any unused

cream ap in the jar to the investigator the following
morning.
The CONTROL axilla should be clean and dry.

NO

antiperspirant is to be applied to this axilla.
SUNDAY, April 9.

Apply the test CREAM ap as directed to the

treated axilla only.

No antiperspirant will be applied to

the control axilla.

The test ap may be worn for the entire

day.

No sweat collection pads will be worn today.

MONDAY, April 10.
TUESDAY, April 11.

Proceed as on SUNDAY.
Apply the test CREAM ap as directed to

the treated axilla only.

Let dry about 1 minute.

Snugly

88

tape the sweat collection pads to the designated axilla.
Wear the pads !or 10 hours.

At the end of the 10-hour

collection period, return the pads to the appropriate
Ziploc bag.

SEAL 'WELL.

Return the pads and bags to the

investigator the following day.
WEDNESDAY, April 12.

Proceed as on TUESDAY. (Sweat

collection day)
THURSDAY, April 13.

Proceed as on TUESDAY. (Sweat

collection day)
FRIDAY, April 14.

Recovery period begins.

(No sweat

Proceed as on FRIDAY.

(No anti-

collected)
SATURDAY, April 15.

(

perspirant applied and no sweat collection)
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WEEK#

4

SUNDAY, April 16, to FRIDAY, April 21, is a recovery
period.

Continue washing axillae with Ivory Soap and

water only.

NO sweat will be collected.

NO anti-

perspirant will be used.
SATURDAY, April 22.

Continue above procedure.

Remove

axillary hair with Surgex as directed on package insert.

(
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NAME

WEEK#
Your TREATED side is the

2
axilla.

AP TRT #

2

The test

LOTION antiperspirant is to be applied to this axilla only.
Your CONTROL side is the

axil la.

NO anti-

perspirant should be applied to this axilla.
REMINDER:

CONTINUE WASHING BOTH AXILLAE WITH IVORY SOAP AND

WATER ONLY FOR THE DURATION OF THE EXPERIMENT.
Application of the test LOTION antiperspirant (ap).
Note the area outlined by axillary hair under your
TREATED axilla.

Make a rectangle of this area.

area to which the ap will be applied.

This is the

Apply the ap provided

for the assigned day to the clean, dry TREATED axilla ONLY.
Apply the lotion ap with the attached cotton swab.

(

Insert

the swab into the lotion and apply to the TREATED axilla.
Try to use the entire sample.

Allow the ap to dry about 1

minute.

Break the swab to fit inside the vial and seal

tightly.

Return the vial, containing the swab and any

remaining lotion, to the investigator the following morning.
The CONTROL axilla should be clean and dry.

NO

antiperspirant is to be applied to this axilla.
SUNDAY, April 23.

Apply the test LOTION ap as directed to

the TREATED axilla only.
to the control axilla.
entire day.

No antiperspirant will be applied
The test ap may be worn for the

No sweat will be collected today.

MONDAY, April 24.
Tuesday, April 25.

Proceed as on SUNDAY.
Apply the test LOTION ap as directed to
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the treated axilla only.

Let dry about 1 minute.

Snugly

tape the sweat collection pads to the designated axillae.
Wear the pads for 10 hours.

At the end of the 10-hour

collection period, return the pads to the appropriate
Ziploc bag.

SEAL WELL.

Return the pads in the bags to

the investigator the following day.
WEDNESDAY, April 26.

Proceed as on TUESDAY. (Sweat collection

day)
THURSDAY, April

27. Proceed as on Tuesday. (Sweat collection

day)
FRIDAY, April 28.

Recovery period begins.

(No ap application

and no sweat collection)

(

SATURDAY, April 29.

Proceed as on FRIDAY.

and no sweat collection)

(

(No ap application
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WEEK#

6

SUNDAY, April 30, to FRIDAY, Hay 5, is a recovery period.
Continue washing axillae with Ivory Soap and water only.
NO sweat will be collected.
SATURDAY, May 6.

NO antiperspirant will be used.

Continue above procedure.

Remove axillary

hair with Surgex as directed on package insert.
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N.AME_ _ _ _ _ _ _ _ _ _ _ _WEEK

Your TREATED side is the

#_ _7...___AP

--- axilla.

TRT

#

3

The test

CLEAR antiperspirant is to be applied to this axilla only.
Your CONfROL side is the

axilla.

NO anti-

perspirant should be applied to this axilla.
REMINDER:

CONTINUE WASHING BOTH AXILLAE WITH IVORY SOAP AND

WATER ONLY FOR THE DURATION OF THE EXPERIMENT.
Application of the test CLEAR antiperspirant (ap).
(The test CLEAR ap is an alcohol-based ap similar to the
manual pump spray).
Note the area outlined by axillary hair under your
TREATED axilla.

(

Make a rectangle 4" by 2" of this area.

This is the area to which the ap will be applied.

Apply

the ap provided for the assigned day to the clean, dry
TREATED axilla only.
attached cotton swab.

Apply the CLEAR ap with the
Insert the swab into the ap and

apply to the TREATED axilla.

Try to use the entire sample.

Allow to dry about 1 minute.

Break the swab to fit inside

the vial and seal tightly.

Return the vial containing the

swab and any remaining ap to the investigator the following
morning.
The CONTROL axilla should be clean and dry.

No

antiperspir_a nt is to be applied to this axilla.
SUNDAY, May

7.

Apply the test CLEAR ap as directed to the

treated axilla only.

No antiperspirant will be applied to

the control axilla.

The test ap ma;y be worn for the entire

day.

No sweat will be collected today.
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MONDAY, May 8.

Proceed as on SUNDAY.

(No sweat col-

lection)
TUESDAY, May 9.
axilla only.

Apply the ap as directed to the TREATED

Let dry about 1 minute.

Snugly tape the

sweat collection pads to the designated axillae.
pads for 10 hours.

Wear the

At the end of the 10-hour collection

period, return the pads to the appropriate Ziploc bag.
SEAL WELL.

Return the pads in the bag to the investigator

the following day.
-:,JEDNESDAY, May 10.

Proceed as on TUESDAY.

(Sweat col-

lection day)
THURSDAY, I1ay 11.

Proceed as on TUESDAY. (Sweat col-

lection day)
(

FRIDAY, May 12.

Recovery period begins.

(No sweat

collection and no antiperspirant applied)
SATURDAY, May 13.

Proceed as on Friday.

collection and no antiperspirant applied)

(No sweat
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WEEK# _8_

SUNDAY, May 14, to FRIDAY, May 19, is a recovery period.
Continue washing axillae with Ivory Soap and water only.
NO sweat will be collected.
SATURDAY, May 20.

NO antiperspirant will be used.

Continue above procedure.

Remove

axillary hair with Surgex as directed on package insert.

(
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NAME

WEEK#
Your TREATED side is the

~

axil la.

AP TRT #

4

The test

STICK antiperspirant is to be applied to this axilla only.
Your CONTROL side is the

axil la.

NO anti-

perspirant should be applied to this axilla.
REMINDER:

CONTINUE WASHING BOTH AXILLAE WITH IVORY SOAP AND

WATER ONLY FOR THE DURATION OF THE EXPERIMENT.
Application of the test STICK antiperspirant (ap).
Note the area outlined by axillary hair under your
TREATED axilla.

Make a rectangle 4" by 2" of this area.

This is the area to which the ap will be applied.

Apply

the ap provided for the assigned day to the clean, dry

(

TREATED axilla ONLY.

The test stick ap may be rubbed in

with your fingers or by using the glassine wrap.
use the entire sample.

Try to

Allow to dry about 1 minute.

Return

the glassine wrap and any unused test stick ap in the jar
to the investigator the following morning.
The CONTROL axilla should be clean and dry.

NO

antiperspirant is to be applied to this axilla.
SUNDAY, May 21.

treated axilla only.

No antiperspirant will be applied to

the control axilla.

The test ap may be worn for the entire

day.

No sweat collection pads will be worn today.

MONDAY, May 22.
TUESDAY, May 23.
(

Apply the test stick ap as directed to the

Proceed as on Sunday.
Apply the test STICK ap as directed to
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the TREATED a.xilla only.

Let dry about 1 minute.

Snugly

tape the sweat collection pads to the designated axillae.
Wear the pads for 10 hours.

At the end of the 10-hour

collection period, return the pads to the appropriate
Ziploc bag.

SEAL WELL.

Return the pads and bag to the

investigator the following day.
WEDNESDAY, May 24.
THURSDAY, MaY 25.

Proceed as on TUESDAY.
Proceed as on TUESDAY.

This is the final day of the antiperspirant study.
Thank you.

(
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